<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugResultsOutput hits="50" offset="0" totalResults="461"><SearchResults><Drug id="66158" name="codeine + chlorpheniramine (sustained-release, cough/cold), Spriaso" lastModificationDate="2016-08-31T00:00:00Z" phaseHighest="Registered"><CompanyOriginator>Lipocine Inc</CompanyOriginator><CompaniesPrimary><Company>Nexgen Pharma Inc</Company><Company>Spriaso LLC</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Histamine receptor antagonist</Action><Action>Opioid receptor agonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Formulation solid oral</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><Summary>Spriaso (under license from Lipocine ) and Nexgen Pharma have developed Tuxarin ER (LPCN-1084, Rinotuss12), a sustained-release combination of opioid receptor agonist, codeine and antihistamine drug, chlorpheniramine, for the treatment of cough and &lt;b&gt;cold&lt;/b&gt; [ 1091560 ], [ 1188257 ], [ 1207699 ], [ 1310396 ], [ 1675084 ], [ 1675094 ], [ 1675177 ]. In November 2014, the FDA accepted a NDA filing for review [ 1675094 ]; in July 2015, the NDA filing was approved by the FDA [ 1675084 ]. In November 2014, Spriaso</Summary><CompaniesSecondary><Company>Lipocine Inc</Company></CompaniesSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action></ActionsSecondary><AddedDate>2010-04-16T00:00:00Z</AddedDate></Drug><Drug id="91711" name="codeine polistirex + chlorpheniramine polistirex (extended-release oral suspension, cough), Aytu BioScience" lastModificationDate="2018-11-13T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Tris Pharma Inc</CompanyOriginator><CompaniesPrimary><Company>Aytu BioScience Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Histamine H1 receptor antagonist</Action><Action>Opioid receptor modulator</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>polistirex and chlorpheniramine polistirex, developed using Tris Pharma's LiquiXR technologyÂ [ 1573544 ], [ 1692199 ], [ 2091246 ]. In the US, the drug is indicated for relief of cough and symptoms associated with upper respiratory allergies or a common &lt;b&gt;cold&lt;/b&gt; in adults aged 18 years and older [ 2003730 ]. In September 2015, the drug was launched in the US [ 1692199 ]. The companies are also developing an oral extended-release liquid formulation CCP-07 and investigating other oral extended-release liquid</Summary><CompaniesSecondary><Company>Tris Pharma Inc</Company><Company>Vernalis plc</Company></CompaniesSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action></ActionsSecondary><AddedDate>2014-06-30T00:00:00Z</AddedDate></Drug><Drug id="81388" name="TRN-125" lastModificationDate="2019-02-01T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Tris Pharma Inc</CompanyOriginator><CompaniesPrimary><Company>Aytu BioScience Inc</Company><Company>Tris Pharma Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Tris Pharma is developing TRN-125 (CCP-08; FP-125), an oral extended-release liquid formulation of a combination drug, for the potential treatment of cough and &lt;b&gt;cold&lt;/b&gt; [ 1402456 ], [ 1573544 ], [ 1388995 ], [ 2081358 ]. In July 2014, proof-of-concept was established for TRN-125 in several studies [ 1578962 ]. In October 2016, an NDA was filed with the US FDA [ 1998121 ]; in August 2017, the FDA issued a Complete Response Letter (CRL) regarding the NDA stating that outstanding items remained that need</Summary><CompaniesSecondary><Company>Vernalis plc</Company></CompaniesSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2012-10-10T00:00:00Z</AddedDate></Drug><Drug id="91396" name="hydrocodone bitartrate + pseudoephedrine hydrochloride" lastModificationDate="2014-05-29T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Hawthorn Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Hawthorn Pharmaceuticals Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Alpha adrenoceptor agonist</Action><Action>Histamine H1 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><Summary>Pernix Therapeutics (following acquisition of Cypress Pharmaceutical) has developed and launched Rezira, an oral solution formulation of the combination of hydrocodone bitartrate and pseudoephedrine hydrochloride for the treatment of cough and common &lt;b&gt;cold&lt;/b&gt; [ 1531087 ], [ 1561782 ], [ 1561760 ]. In June 2011, the product was approved and subsequently launched [ 1561782 ], [ 1561760 ].</Summary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action></ActionsSecondary><AddedDate>2014-05-26T00:00:00Z</AddedDate></Drug><Drug id="91793" name="TRN-123" lastModificationDate="2019-01-28T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Tris Pharma Inc</CompanyOriginator><CompaniesPrimary><Company>Tris Pharma Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Tris Pharma is investigating TRN-123 (CCP-06), an oral extended-release liquid formulation combination drug, for the potential treatment of cough and &lt;b&gt;cold&lt;/b&gt; [ 1402456 ], [ 1388995 ], [ 2081358 ], [ 2044647 ]. In February 2017, proof-of-concept (POC) was planned to be achieved by the end of 2017 [ 1901896 ]; in September 2017, POC was expected to be achieved in the 2017/2018 financial year [ 1998121 ]. Tris Pharma is also developing oral extended-release liquid formulations CCP-01 and CCP-07 and also</Summary><CompaniesSecondary><Company>Vernalis plc</Company></CompaniesSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-07-07T00:00:00Z</AddedDate></Drug><Drug id="91794" name="TRN-124" lastModificationDate="2019-01-28T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Tris Pharma Inc</CompanyOriginator><CompaniesPrimary><Company>Tris Pharma Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Tris Pharma is developing TRN-124 (CCP-07; FP-124), an oral extended-release liquid formulation of a combination drug, for the potential treatment of cough and &lt;b&gt;cold&lt;/b&gt; [ 1402456 ], [ 1388995 ], [ 2081358 ], [ 2044647 ]. In September 2016, an NDA was accepted by the FDA with a PDUFA date of April 20, 2017 [ 1793657 ]; in April 2017, the FDA issued a Complete Response Letter (CRL) identifying outstanding items that needed addressing prior to resubmission and approval of the NDA. No concerns were raised</Summary><CompaniesSecondary><Company>Vernalis plc</Company></CompaniesSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-07-04T00:00:00Z</AddedDate></Drug><Drug id="102868" name="carbomer-980" lastModificationDate="2017-04-27T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>GlaxoSmithKline plc</CompanyOriginator><CompaniesPrimary><Company>GlaxoSmithKline plc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication></IndicationsPrimary><Technologies><Technology>Nasal formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><Summary>GlaxoSmithKline is developing carbomer-980 (1146A), as a nasal spray, for the potential treatment of common &lt;b&gt;cold&lt;/b&gt; [ 1781044 ], [ 1889199 ]. In December 2016, a phase II study was initiated in the US; in June 2017, the trial was completed [ 1889199 ].</Summary><ActionsSecondary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2016-07-25T00:00:00Z</AddedDate></Drug><Drug id="91390" name="hydrocodone bitartrate + chlorpheniramine maleate + pseudoephedrine hydrochloride" lastModificationDate="2014-05-29T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Hawthorn Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Hawthorn Pharmaceuticals Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Alpha adrenoceptor agonist</Action><Action>Histamine H1 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><Summary> acquisition of Cypress Pharmaceutical) has developed and launched Zutripro, an oral solution formulation of the combination of hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride for the treatment of cough and common &lt;b&gt;cold&lt;/b&gt; [ 1357763 ], [ 1353551 ], [ 1561756 ], [ 1561760 ]. In June 2011, the product was approved and subsequently launched [ 1561756 ], [ 1561760 ].</Summary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action></ActionsSecondary><AddedDate>2014-05-26T00:00:00Z</AddedDate></Drug><Drug id="83624" name="hydrocodone bitartrate + chlorpheniramine maleate (cough), Hawthorn Pharmaceuticals" lastModificationDate="2014-04-09T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Hawthorn Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Hawthorn Pharmaceuticals Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><Summary> solution formulation of the combination of hydrocodone bitartrate, an antitussive and chlorpheniramine maleate, a histamine-1 (H1) receptor antagonist, for the treatment of cough and symptoms associated with upper respiratory allergies or a common &lt;b&gt;cold&lt;/b&gt; in adults 18 years of age and older [ 1387478 ], [ 1393035 ]. By March 2014, the drug had been launched [ 1536010 ].</Summary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action></ActionsSecondary><AddedDate>2013-03-04T00:00:00Z</AddedDate></Drug><Drug id="91792" name="TRN-112" lastModificationDate="2019-01-28T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Tris Pharma Inc</CompanyOriginator><CompaniesPrimary><Company>Tris Pharma Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Tris Pharma is investigating TRN-112 (CCP-05), an oral extended-release liquid formulation combination drug, for the potential treatment of cough and &lt;b&gt;cold&lt;/b&gt; [ 1402456 ], [ 1388995 ], [ 2081358 ], [ 2044647 ]. In February 2017, proof-of-concept (POC) data were expected by the end of 2017 [ 1901896 ]; in September 2017, POC was expected to be achieved in the 2017/2018 financial year [ 1998121 ]. Tris Pharma is also developing oral extended-release liquid formulations CCP-01 and CCP-07 , and are investigating</Summary><CompaniesSecondary><Company>Vernalis plc</Company></CompaniesSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-07-07T00:00:00Z</AddedDate></Drug><Drug id="78127" name="sutimlimab" lastModificationDate="2019-06-07T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Bioverativ Inc</CompanyOriginator><CompaniesPrimary><Company>Bioverativ Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Autoimmune hemolytic anemia</Indication><Indication>Bullous pemphigoid</Indication><Indication>Cold agglutinin disease</Indication><Indication>End stage renal disease</Indication><Indication>Thrombocytopenia</Indication><Indication>Transplant rejection</Indication></IndicationsPrimary><ActionsPrimary><Action>Complement C1s subcomponent inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><Summary>mAb, TNT-003, and a serine protease-specific (C1s) classical complement pathway inhibitor, for the potential iv treatment of complement-mediated disorders, primarily &lt;b&gt;cold&lt;/b&gt; agglutinin disease [ 1292817 ], [ 1473514 ], [ 1680992 ], [ 1941868 ], [ 1991164 ]. In November 2017, two phase III trials (Cardinal and Cadenza) were initiated in &lt;b&gt;cold&lt;/b&gt; agglutinin disease patients with and without a recent history of blood transfusions [ 1991166 ], [ 1991170 ], [ 2005000 ]; in June 2018, trials were expected to complete</Summary><CompaniesSecondary><Company>True North Therapeutics</Company><Company>iPierian Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Hematological disease</Indication><Indication>Neurodegenerative disease</Indication><Indication>Renal disease</Indication></IndicationsSecondary><ActionsSecondary><Action>Immunosuppressant</Action></ActionsSecondary><AddedDate>2012-05-23T00:00:00Z</AddedDate></Drug><Drug id="92280" name="guaifenesin (oral extended release microcapsule formulation/powder, common cold), Orbis Biosciences" lastModificationDate="2018-04-02T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Orbis Biosciences Inc</CompanyOriginator><CompaniesPrimary><Company>Orbis Biosciences Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Respiratory congestion</Indication></IndicationsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Liquid formulation</Technology><Technology>Microcapsule formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>investigating ORB-103, a 12-hr extended release microcapsule oral formulation of guaifenesin, an expectorant, as a powder formulation, using the company'sÂ Optimum platform in Precision Particle FabricationÂ technology, for the potential treatment of common &lt;b&gt;cold&lt;/b&gt; and chest congestion [ 1586331 ], [ 1724118 ]. In August 2014, the drug was listed in preclinical development [ 1586331 ]; in March 2018, this was still the case [ 2012773 ].</Summary><ActionsSecondary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-08-23T00:00:00Z</AddedDate></Drug><Drug id="90470" name="KX-001" lastModificationDate="2019-05-21T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Beijing CoSci Med-Tech Co Ltd</CompanyOriginator><CompaniesPrimary><Company>Beijing CoSci Med-Tech Co Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication></IndicationsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>extended-release capsule formulation of a combination of undisclosed drugs, for the potential treatment of symptoms associated with common &lt;b&gt;cold&lt;/b&gt; and influenza. In March 2014, the product was under development [ 1537835 ]. In August 2016, development was still ongoing [ 1787232 ]. The company is also investigating KX-002 for the potential treatment of symptoms associated with common &lt;b&gt;cold&lt;/b&gt; and influenza.</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-04-09T00:00:00Z</AddedDate></Drug><Drug id="100187" name="BIVV-020" lastModificationDate="2019-01-21T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Bioverativ Inc</CompanyOriginator><CompaniesPrimary><Company>Bioverativ Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cold agglutinin disease</Indication></IndicationsPrimary><ActionsPrimary><Action>Complement C1s subcomponent inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>Therapeutics ), now a wholly owned subsidiary of Sanofi , is investigating BIVV-020 (formerly TNT-020), a lead next-generation follow-on mAb targeting the serine protease-specific (C1s) classical complement pathway, for the potential subcutaneous treatment of &lt;b&gt;cold&lt;/b&gt; agglutinin disease [ 2049826 ]. In December 2016, the program was in preclinical development [ 1888680 ]. In June 2018, development was ongoing [ 2049826 ]. The company was previously investigating TNT-010, for the potential treatment of classical </Summary><CompaniesSecondary><Company>True North Therapeutics</Company></CompaniesSecondary><IndicationsSecondary><Indication>Immune disorder</Indication></IndicationsSecondary><ActionsSecondary><Action>Immunomodulator</Action></ActionsSecondary><AddedDate>2015-12-21T00:00:00Z</AddedDate></Drug><Drug id="90471" name="KX-002" lastModificationDate="2016-08-13T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Beijing CoSci Med-Tech Co Ltd</CompanyOriginator><CompaniesPrimary><Company>Beijing CoSci Med-Tech Co Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication></IndicationsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>extended-release capsule formulation of a combination of undisclosed drugs, for the potential treatment of symptoms associated with common &lt;b&gt;cold&lt;/b&gt; and influenza. In March 2014, the product was under development [ 1537835 ]. In August 2016, development was still ongoing [ 1787232 ]. The company is also investigating KX-001 for the potential treatment of symptoms associated with common &lt;b&gt;cold&lt;/b&gt; and influenza.</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-04-09T00:00:00Z</AddedDate></Drug><Drug id="97386" name="forsythoside (oral/capsule), Guangdong Lewwin Pharmaceutical Research Institute" lastModificationDate="2019-05-15T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Guangdong Lewwin Pharmaceutical Research Institute Co Ltd</CompanyOriginator><CompaniesPrimary><Company>Guangdong Lewwin Pharmaceutical Research Institute Co Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication></IndicationsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Pharmaceutical Research Institute is investigating an oral capsule formulation of forsythoside (forsythoside A), extracted from fructus forsythiae, for the potential treatment of fever caused by common &lt;b&gt;cold&lt;/b&gt; and flu [ 1665301 ]. It is also for the potential use to relieve the headache and sore throat due to &lt;b&gt;cold&lt;/b&gt; [ 1937040 ]. In June 2015, an IND application was filed in China [ 1665301 ], [ 1666942 ]; in December 2016, the application was approved [ 1937047 ]. In June 2017, a phase I trial was planned in</Summary><ActionsSecondary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate></AddedDate></Drug><Drug id="47733" name="canakinumab" lastModificationDate="2019-02-26T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Novartis AG</CompanyOriginator><CompaniesPrimary><Company>Novartis AG</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Adult onset Stills disease</Indication><Indication>Autoimmune disease</Indication><Indication>Behcets disease</Indication><Indication>CINCA syndrome</Indication><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Familial mediterranean fever</Indication><Indication>Fever</Indication><Indication>Gout</Indication><Indication>Juvenile rheumatoid arthritis</Indication><Indication>Metastatic breast cancer</Indication><Indication>Muckle Wells syndrome</Indication><Indication>Non-small-cell lung cancer</Indication><Indication>Sarcoidosis</Indication><Indication>Sickle cell anemia</Indication><Indication>Stage III melanoma</Indication><Indication>Stage IV melanoma</Indication></IndicationsPrimary><ActionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>the treatment of cryopyrin-associated periodic syndromes (CAPS) in patients over 4 years of age, including familial &lt;b&gt;cold&lt;/b&gt; auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), for active systemic juvenile idiopathic arthritis (SJIA) in...familial &lt;b&gt;cold&lt;/b&gt; urticaria (FCU) presenting with signs and symptoms beyond &lt;b&gt;cold&lt;/b&gt;-induced urticaria skin rash, for the symptomatic treatment of adults with frequent gouty arthritis attacks, and for adult-onset Still's</Summary><IndicationsSecondary><Indication>Abdominal aortic aneurysm</Indication><Indication>Age related macular degeneration</Indication><Indication>Asthma</Indication><Indication>Atherosclerosis</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Immune disorder</Indication><Indication>Insulin dependent diabetes</Indication><Indication>Kawasaki disease</Indication><Indication>Non-insulin dependent diabetes</Indication><Indication>Osteoarthritis</Indication><Indication>Polymyalgia rheumatica</Indication><Indication>Rheumatoid arthritis</Indication><Indication>Vasculitis</Indication><Indication>Xerophthalmia</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondary><AddedDate>2003-11-21T00:00:00Z</AddedDate></Drug><Drug id="10454" name="rilonacept" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Regeneron Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Kiniksa Pharmaceuticals Ltd</Company><Company>Neovii Biotech GmbH</Company><Company>Regeneron Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Autoinflammatory disease</Indication><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Familial mediterranean fever</Indication><Indication>Muckle Wells syndrome</Indication><Indication>Pericarditis</Indication></IndicationsPrimary><ActionsPrimary><Action>Interleukin-1 alpha ligand inhibitor</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Protein fusion</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>indicated in the US for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial &lt;b&gt;cold&lt;/b&gt; auto-inflammatory syndrome (FCAS) and Muckle Wells syndrome (MWS) in adults and children aged 12 years and older...including &lt;b&gt;cold&lt;/b&gt; contact urticaria and scleroderma. In June 2014, an investigator-sponsored, phase II trial for &lt;b&gt;cold&lt;/b&gt; contact urticaria was initiated; in January 2017, the trial was expected to complete in April 2018 [ 1572919 ]. In</Summary><CompaniesSecondary><Company>Novartis AG</Company></CompaniesSecondary><IndicationsSecondary><Indication>Anemia</Indication><Indication>Coronary atherosclerosis</Indication><Indication>Gout</Indication><Indication>Juvenile rheumatoid arthritis</Indication><Indication>Osteoarthritis</Indication><Indication>Polymyalgia rheumatica</Indication><Indication>Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="81545" name="BCG polysaccharide and nucleic acid, Zhejiang Wanma Pharmaceutical Chemical" lastModificationDate="2012-10-26T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Zhejiang Wanma Pharmaceutical Chemical Co Ltd</CompanyOriginator><CompaniesPrimary><Company>Zhejiang Wanma Pharmaceutical Chemical Co Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Asthma</Indication><Indication>Chronic bronchitis</Indication><Indication>Common cold</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Oligosaccharide</Technology><Technology>Solution</Technology></Technologies><Summary>Zhejiang Wanma Pharmaceutical Chemical has developed and launched Di Su, a Bacillus Calmette - Guerin (BCG) polysaccharide and nucleic acid preparation, for the im prevention and treatment of chronic bronchitis, &lt;b&gt;cold&lt;/b&gt; and asthma. It was assumed that the product was launched in China shortly after its approval there in 2002 [ 1333817 ], [ 1333819 ].</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Antiviral</Action><Action>Immunostimulant</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2012-10-26T00:00:00Z</AddedDate></Drug><Drug id="75299" name="APL-2 (subcutaneous), Apellis" lastModificationDate="2019-07-01T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>University of Pennsylvania</CompanyOriginator><CompaniesPrimary><Company>Apellis Pharmaceuticals Inc</Company><Company>SFJ Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Autoimmune hemolytic anemia</Indication><Indication>Cold agglutinin disease</Indication><Indication>Glomerular disease</Indication><Indication>IgA nephropathy</Indication><Indication>Ischemic stroke</Indication><Indication>Lupus nephritis</Indication><Indication>Membranous glomerulonephritis</Indication><Indication>Paroxysmal nocturnal hemoglobinuria</Indication></IndicationsPrimary><ActionsPrimary><Action>Complement C3 inhibitor</Action><Action>Complement cascade inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>of APL-2 monotherapy as a first-line treatment for PNH [ 2024235 ]. In February 2019, SFJ stated that it would support the program [ 2124533 ]. Apellis is also developing the drug for the potential treatment of autoimmune hemolytic anemia (wAIHA) or &lt;b&gt;cold&lt;/b&gt; agglutinin disease (CAD) and complement-dependent nephropathies, including IgA nephropathy, C3 glomerulopathy, primary membranous nephropathy and lupus nephritis [ 1973298 ], [ 2015865 ]. In August 2017, a phase II trial in patients with wAIHA and </Summary><CompaniesSecondary><Company>University of Pennsylvania</Company></CompaniesSecondary><ActionsSecondary><Action>Anti-inflammatory</Action></ActionsSecondary><AddedDate>2012-01-04T00:00:00Z</AddedDate></Drug><Drug id="84511" name="BCG polysaccharide and nucleic acid, Jilin Yatai Bio-Pharmaceutical" lastModificationDate="2013-04-16T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Jilin Yatai Bio-Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company>Jilin Yatai Bio-Pharmaceutical Co Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Allergy</Indication><Indication>Asthma</Indication><Indication>Cancer</Indication><Indication>Chronic bronchitis</Indication><Indication>Common cold</Indication><Indication>Immune complex disease</Indication><Indication>Infectious disease</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable formulation</Technology><Technology>Oligonucleotide</Technology><Technology>Oligosaccharide</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Solution</Technology></Technologies><Summary>Jilin Yatai Bio-Pharmaceutical has developed and launched a Bacillus Calmette-Guerin (BCG) polysaccharide and nucleic acid preparation, for the injectable treatment of chronic bronchitis, &lt;b&gt;cold&lt;/b&gt;, asthma, chronic infection, allergy, immune complex disease and cancer. It was assumed that the product was launched in China shortly after its approval there in 2004 [ 1385804 ], [ 1403628 ].</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Anticancer</Action><Action>Antiviral</Action><Action>Immunostimulant</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2013-04-16T00:00:00Z</AddedDate></Drug><Drug id="81679" name="BCG polysaccharide + nucleic acid injection (im, immunomodulator), Hunan Jiuzhitang-Siqi Biopharmaceutical" lastModificationDate="2014-07-01T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Hunan Jiuzhitang-Siqi Biopharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company>Hunan Jiuzhitang-Siqi Biopharmaceutical Co Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Asthma</Indication><Indication>Common cold</Indication><Indication>Dermatological disease</Indication><Indication>Eczema</Indication><Indication>Psoriasis</Indication><Indication>Respiratory disease</Indication><Indication>Urticaria</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Oligonucleotide</Technology><Technology>Oligosaccharide</Technology></Technologies><Summary>and launched a BCG (Bacillus Calmette - Guerin) polysaccharide and nucleic acid injection, an immunomodulator for the treatment of skin diseases including urticaria, eczema, psoriasis and others, as well as respiratory diseases such like asthma and &lt;b&gt;cold&lt;/b&gt;. The product was assumed to be launched in China shortly after its approval there in 2002 [ 1335871 ], [ 1335872 ].</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunomodulator</Action><Action>Systemic antipsoriatic product</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2012-11-23T00:00:00Z</AddedDate></Drug><Drug id="7274" name="anakinra" lastModificationDate="2019-06-27T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Amgen Inc</CompanyOriginator><CompaniesPrimary><Company>MegaPharm Ltd</Company><Company>Menarini Asia-Pacific</Company><Company>Swedish Orphan Biovitrum AB</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Adult onset Stills disease</Indication><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Gout</Indication><Indication>Inner ear disease</Indication><Indication>Juvenile rheumatoid arthritis</Indication><Indication>Muckle Wells syndrome</Indication><Indication>Rheumatoid arthritis</Indication><Indication>Ulcerative colitis</Indication></IndicationsPrimary><ActionsPrimary><Action>Type I IL-1 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of CAPS, including NOMID/chronic infantile neurological, cutaneous, articular syndrome (CINCA), Muckle-Wells syndrome (MWS) and familial &lt;b&gt;cold&lt;/b&gt; auto inflammatory syndrome (FCAS) [ 2021761 ]; and in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA</Summary><CompaniesSecondary><Company>Amgen Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Asthma</Indication><Indication>Inflammatory bowel disease</Indication><Indication>Neuritis</Indication><Indication>Ocular inflammation</Indication><Indication>Osteoarthritis</Indication><Indication>Psoriasis</Indication><Indication>Sepsis</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="71225" name="codeine + guaifenesin (sustained release, cough), Spriaso/Nexgen Pharma" lastModificationDate="2018-07-30T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Lipocine Inc</CompanyOriginator><CompaniesPrimary><Company>Nexgen Pharma Inc</Company><Company>Spriaso LLC</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Opioid receptor agonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><Summary>clinical development [ 1675233 ]. In July 2018, this was still the case [ 2057943 ]. In July 2015, Spriaso was seeking to outlicense the drug [ 1675233 ]. Spriaso and Nexgen Pharma were previously developing the drug, for the potential treatment of &lt;b&gt;cold&lt;/b&gt; [ 1091257 ], [ 1091560 ], [ 1207699 ], [ 1310396 ], [ 1675233 ], [ 1675177 ]. However, no further development was reported for this indication.</Summary><CompaniesSecondary><Company>Lipocine Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Expectorant</Action></ActionsSecondary><AddedDate>2011-05-04T00:00:00Z</AddedDate></Drug><Drug id="66159" name="hydrocodone + guaifenesin (sustained release, cough), Spriaso/Nexgen Pharma" lastModificationDate="2018-07-30T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Lipocine Inc</CompanyOriginator><CompaniesPrimary><Company>Nexgen Pharma Inc</Company><Company>Spriaso LLC</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Opioid receptor agonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><Summary>development for cough [ 1675233 ]. In July 2018, this was still the case [ 2057943 ]. In July 2015, Spriaso was seeking to outlicense the drug [ 1675233 ]. Spriaso and Nexgen Pharma were previously developing the drug, for the potential treatment of &lt;b&gt;cold&lt;/b&gt; [ 1091257 ], [ 1091560 ], [ 1207699 ], [ 1310396 ], [ 1675233 ], [ 1675177 ]. However, no further development was reported for this indication.</Summary><CompaniesSecondary><Company>Lipocine Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Expectorant</Action></ActionsSecondary><AddedDate>2010-04-16T00:00:00Z</AddedDate></Drug><Drug id="116503" name="PHLPP2 CRISPR/Cas9 gene therapy (lentiviral vector, prostate cancer), Cold Spring Harbor Laboratory" lastModificationDate="2019-05-22T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Cold Spring Harbor Laboratory</CompanyOriginator><CompaniesPrimary><Company>Cold Spring Harbor Laboratory</Company></CompaniesPrimary><IndicationsPrimary><Indication>Prostate tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>CRISPR associated endonuclease Cas9 modulator</Action><Action>PHLPP2 gene inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>&lt;b&gt;Cold&lt;/b&gt; Spring Harbor Laboratory is investigating lentiviral vector delivering CRISPR/Cas9, which targets and deletes mutated Pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2), for the potential treatment of prostate cancer [ 2151907 ]. In May 2019, preclinical data were published [ 2151907 ], [ 2152774 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Lentivirus based gene therapy</Action></ActionsSecondary><AddedDate>2019-05-22T00:00:00Z</AddedDate></Drug><Drug id="103205" name="CG-0161" lastModificationDate="2018-03-28T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Cold Genesys Inc</CompanyOriginator><CompaniesPrimary><Company>Cold Genesys Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>Cytotoxic T-lymphocyte protein-4 inhibitor</Action></ActionsPrimary><Technologies><Technology>Antibody</Technology><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>&lt;b&gt;Cold&lt;/b&gt; Genesys is investigating CG-0161, an anti-CTLA-4 antibody for the potential treatment of cancer. In August 2016, the antibody was listed as being in preclinical development [ 1789986 ].</Summary><ActionsSecondary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2016-08-31T00:00:00Z</AddedDate></Drug><Drug id="61760" name="hydrocodone + antihistamine (allergic rhinitis), Cornerstone Therapeutics" lastModificationDate="2014-02-05T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Cornerstone BioPharma Inc</CompanyOriginator><ActionsPrimary><Action>Histamine receptor antagonist</Action><Action>Opioid receptor agonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>daily) oral suspension combination of the antitussive hydrocodone and an antihistamine, formulated using Neos ' Dynamic Time Release Suspension (DTRS) technology and Coating Place 's drug resin complex technology, for potential use in the treatment of &lt;b&gt;cold&lt;/b&gt; and cough [ 959133 ], [ 958694 ], [ 959176 ], [ 1222551 ]. In November 2008, the company anticipated that only pharmacokinetic studies would be required for approval; at that time, launch was expected in 2010 [ 959133 ]. In March 2011, CRTX-069 was</Summary><CompaniesSecondary><Company>Chiesi USA Inc</Company><Company>Cornerstone BioPharma Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action></ActionsSecondary><AddedDate>2008-11-04T00:00:00Z</AddedDate></Drug><Drug id="67620" name="CRTX-074" lastModificationDate="2013-09-25T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Chiesi USA Inc</CompanyOriginator><Technologies><Technology>Drug combination</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>be discontinued. Cornerstone Therapeutics was investigating CRTX-074, a combination product formulated using Neos â Dynamic Time Release Suspension (DTRS) technology and Coating Place âs drug resin complex technology, for the potential treatment of &lt;b&gt;cold&lt;/b&gt; and cough [ 1120937 ], [ 1121594 ], [ 1222551 ]. By December 2009, the company anticipated filing a marketing application in 2011 [ 1120937 ]; in March 2011, the timeline for filing was under review [ 1222551 ].</Summary><CompaniesSecondary><Company>Chiesi USA Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2010-08-09T00:00:00Z</AddedDate></Drug><Drug id="67619" name="CRTX-072" lastModificationDate="2014-02-07T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Chiesi USA Inc</CompanyOriginator><Technologies><Technology>Drug combination</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>be discontinued. Cornerstone Therapeutics was investigating CRTX-072, a combination product formulated using Neos ' Dynamic Time Release Suspension (DTRS) technology and Coating Place 's drug resin complex technology, for the potential treatment of &lt;b&gt;cold&lt;/b&gt; and cough [ 1120937 ], [ 1121594 ], [ 1222551 ]. By December 2009, the company anticipated filing a marketing application in 2011 [ 1120937 ]; in March 2011, the submission was expected in 2013 [ 1222551 ].</Summary><CompaniesSecondary><Company>Chiesi USA Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2010-08-09T00:00:00Z</AddedDate></Drug><Drug id="91790" name="CCP-03" lastModificationDate="2014-07-08T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Vernalis plc</CompanyOriginator><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Tris Pharma and Vernalis were investigating an oral extended-release liquid formulation of a combination drug, CCP-03, for the potential treatment of cough and &lt;b&gt;cold&lt;/b&gt; [ 1329712 ], [ 1388995 ]. However, in April 2013, the program was no longer listed on the company's development pipeline [ 1402456 ].</Summary><CompaniesSecondary><Company>Tris Pharma Inc</Company><Company>Vernalis plc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-07-03T00:00:00Z</AddedDate></Drug><Drug id="91783" name="CCP-02" lastModificationDate="2014-07-08T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Vernalis plc</CompanyOriginator><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Tris Pharma and Vernalis were investigating an oral extended-release liquid formulation of a combination drug, CCP-02, for the potential treatment of cough and &lt;b&gt;cold&lt;/b&gt; [ 1329712 ], [ 1388995 ]. However, in April 2013, the program was no longer listed on the company's development pipeline [ 1402456 ].</Summary><CompaniesSecondary><Company>Tris Pharma Inc</Company><Company>Vernalis plc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>Cough</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-07-03T00:00:00Z</AddedDate></Drug><Drug id="110396" name="antisense oligonucleotide (familial dysautonomia), Cold spring harbor laboratory/Ionis Pharmaceuticals" lastModificationDate="2018-05-11T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Cold Spring Harbor Laboratory</CompanyOriginator><CompaniesPrimary><Company>Cold Spring Harbor Laboratory</Company><Company>Ionis Pharmaceuticals Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Familial dysautonomia</Indication></IndicationsPrimary><ActionsPrimary><Action>IKBKAP gene modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligonucleotide antisense</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>&lt;b&gt;Cold&lt;/b&gt; spring harbor laboratory , in collaboration with Ionis Pharmaceuticals , is investigating an antisense oligonucleotide (ASO), which corrects an error in RNA splicing of IKBKAP gene, to restore production of IKAP protein, for the potential treatment of familial dysautonomia [ 2029325 ], [ 2030085 ].</Summary><ActionsSecondary><Action>Antisense oligonucleotide inhibitor</Action></ActionsSecondary><AddedDate>2018-05-11T00:00:00Z</AddedDate></Drug><Drug id="86749" name="topical broad-spectrum antiviral agent (nasal spray, colds), Firebrick Pharma" lastModificationDate="2018-03-28T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Firebrick Pharma Pty Ltd</CompanyOriginator><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. Firebrick Pharma was investigating a topical, broad-spectrum, microbicidal spray designed to arrest &lt;b&gt;cold&lt;/b&gt; symptoms by destroying all causative viruses present in nasal mucus [ 1461167 ].</Summary><CompaniesSecondary><Company>Firebrick Pharma Pty Ltd</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2013-08-19T00:00:00Z</AddedDate></Drug><Drug id="49543" name="CG-0070" lastModificationDate="2019-05-30T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Novartis AG</CompanyOriginator><CompaniesPrimary><Company>Cold Genesys Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Bladder tumor</Indication><Indication>Solid tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>CSF2 gene stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravesical formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>&lt;b&gt;Cold&lt;/b&gt; Genesys , under license from ANI Pharmaceuticals Inc (formerly BioSante Pharmaceuticals; following its merger with Cell Genesys , which originally licensed the product from Novartis ), is developing CG-0070, oncolytic adenovirus engineered with tumor-specific transcriptional response elements and encoding human GM-CSF, for the potential intravesical treatment of bladder cancer, including bacillus Calmette-Guerin (BCG)-resistant bladder cancer, muscle invasive bladder cancer (MIBC) and non-muscle</Summary><CompaniesSecondary><Company>ANI Pharmaceuticals Inc</Company><Company>Cell Genesys Inc</Company><Company>Novartis AG</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Adenovirus based gene therapy</Action><Action>Anticancer</Action></ActionsSecondary><AddedDate>2004-04-07T00:00:00Z</AddedDate></Drug><Drug id="47802" name="pleconaril (intranasal), Merck &amp; Co" lastModificationDate="2016-09-29T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Sanofi-Synthelabo</CompanyOriginator><Technologies><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Co , following its acquisition of Schering-Plough and under license from ViroPharma (who obtained rights from Sanofi-Synthelabo ), was developing an intranasal formulation of pleconaril for the potential prevention of asthma exacerbation and common &lt;b&gt;cold&lt;/b&gt; symptoms in asthmatic subjects exposed to rhinovirus [ 514747 ], [ 574494 ], [ 1054580 ]. In May 2005, the spray was listed as in phase II studies for this indication [ 603620 ]; it was still listed as in phase II in October 2009 [ 1054779 ]. However</Summary><CompaniesSecondary><Company>Merck &amp; Co Inc</Company><Company>Sanofi-Synthelabo</Company><Company>Schering-Plough Corp</Company><Company>Shire ViroPharma, Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication></IndicationsSecondary><ActionsSecondary><Action>Unspecified drug target</Action><Action>Viral replication inhibitor</Action></ActionsSecondary><AddedDate>2003-11-26T00:00:00Z</AddedDate></Drug><Drug id="86351" name="dexibuprofen + levocetirizine (oral sustained-release, inflammatory disease), Lijun Pharmaceutical" lastModificationDate="2018-04-21T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Xi'an Lijun Pharmaceutical Co Ltd</CompanyOriginator><ActionsPrimary><Action>Cyclooxygenase inhibitor</Action><Action>Histamine H1 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><Summary>discontinued. Xi'an Lijun Pharmaceutical (a subsidiary of Lijun International Pharmaceutical ) was investigating a double-layer sustained-release tablet formulation of a combination of dexibuprofen and levocetirizine , for the potential oral treatment of &lt;b&gt;cold&lt;/b&gt;. In February 2012, an IND was filed with the SFDA; in March 2013, the IND application was approved in China [ 1457564 ], [ 1452499 ]. In September 2014, a phase I trial was planned to be initiated [ 1594776 ].</Summary><CompaniesSecondary><Company>Xi'an Lijun Pharmaceutical Co Ltd</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiviral</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondary><AddedDate>2013-07-29T00:00:00Z</AddedDate></Drug><Drug id="99607" name="BNT-014" lastModificationDate="2018-03-30T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Bionaturis</CompanyOriginator><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. Bionaturis was investigating BNT-014, a virus-like particle (VLP) vaccine candidate, for the potential prevention of common &lt;b&gt;cold&lt;/b&gt; (human rhinovirus). In October 2015, the vaccine was listed as being in proof of concept in vivo studies [ 1707168 ].</Summary><CompaniesSecondary><Company>Bionaturis</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication></IndicationsSecondary><ActionsSecondary><Action>Prophylactic vaccine</Action></ActionsSecondary><AddedDate>2015-10-29T00:00:00Z</AddedDate></Drug><Drug id="39258" name="MRL-2471" lastModificationDate="2009-06-18T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Maruishi Pharmaceutical Co Ltd</CompanyOriginator><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>reported for some time, this program is assumed to be discontinued. Maruishi , in collaboration with Kanazawa University , was investigating MRL-2471, an antiviral that inhibits proliferation of rhinovirus, for the potential treatment of the common &lt;b&gt;cold&lt;/b&gt; [ 447955 ].</Summary><CompaniesSecondary><Company>Maruishi Pharmaceutical Co Ltd</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>Rhinovirus infection</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2002-04-16T00:00:00Z</AddedDate></Drug><Drug id="76244" name="2C inhibitors (hand-foot-mouth syndrome/common cold/aseptic meningitis/poliomyelitis/chronic obstructive pulmonary disease/acute hemorrhagic conjunctivitis/myopericarditis), KRICT" lastModificationDate="2016-06-08T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Korea Research Institute of Chemical Technology</CompanyOriginator><ActionsPrimary><Action>Protein phosphatase 1A inhibitor</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary> be discontinued. Korea Research Institute of Chemical Technology (KRICT) was investigating KR-23247, an antiviral 2C inhibitor, and its analogs for the potential treatment of hand-foot-mouth syndrome associated with picornavirus infections, common &lt;b&gt;cold&lt;/b&gt;, aseptic meningitis, poliomyelitis, chronic obstructive pulmonary disease, acute hemorrhagic conjunctivitis associated with enterovirus 70 and Coxsackie virus A24 infections and myopericarditis [ 1266174 ], [ 1266159 ]. In May 2013, preclinical studies</Summary><CompaniesSecondary><Company>Korea Research Institute of Chemical Technology</Company></CompaniesSecondary><IndicationsSecondary><Indication>Aseptic meningitis</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Common cold</Indication><Indication>Coxsackie virus infection</Indication><Indication>Enterovirus infection</Indication><Indication>Myocarditis</Indication><Indication>Pericarditis</Indication><Indication>Picornavirus infection</Indication><Indication>Poliovirus infection</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antiviral</Action></ActionsSecondary><AddedDate>2012-02-25T00:00:00Z</AddedDate></Drug><Drug id="8846" name="NPC-567" lastModificationDate="2003-04-30T00:00:00Z" phaseHighest="Discontinued"><CompanyOriginator>Scios Inc</CompanyOriginator><ActionsPrimary><Action>Bradykinin receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Peptide</Technology></Technologies><Summary>clinical trials in the US with Scios Nova as a potential treatment for asthma, and was also being investigated as a topical treatment for burns, but all development of the compound has been discontinued [ 328061 ]. Previous development for the common &lt;b&gt;cold&lt;/b&gt; was discontinued in January 1990 [ 168294 ]. It inhibited antigen-induced respiratory effects in sensitized guinea pigs and sheep [ 228805 ]. Scios Nova owns the patent, US-04693993, filed in 1987, for which equivalents exist in 28 countries.</Summary><CompaniesSecondary><Company>Scios Inc</Company><Company>SmithKline Beecham plc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Asthma</Indication><Indication>Common cold</Indication><Indication>Skin burns</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiviral</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="13314" name="enviroxime analogs (antiviral), Lilly" lastModificationDate="2008-03-11T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Eli Lilly &amp; Co</CompanyOriginator><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. Eli Lilly was investigating a series of analogs of enviroxime, which has included LY-178700, LY-207459, LY-222936, LY-354400 and LY-353536, for the potential treatment of rhinovirus and picornavirus infections [ 216642 ]. By March 2002 evaluation of vinyl acetylenic analogs had been discontinued [ 444997 ]. Lilly has also investigated a chemically distinct series of compounds as rhinovirus protease</Summary><CompaniesSecondary><Company>Eli Lilly &amp; Co</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>Picornavirus infection</Indication><Indication>Rhinovirus infection</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiviral</Action><Action>Unspecified drug target</Action><Action>Viral replication inhibitor</Action></ActionsSecondary><AddedDate>1996-09-13T00:00:00Z</AddedDate></Drug><Drug id="11916" name="bradykinin antagonist, Pfizer" lastModificationDate="2002-05-29T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Pfizer Pharmaceuticals Inc</CompanyOriginator><ActionsPrimary><Action>Bradykinin receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Pfizer was investigating a series of novel dihydropyridine analog bradykinin antagonists for their potential in the treatment of inflammation, cardiovascular disease, pain, common &lt;b&gt;cold&lt;/b&gt; and allergy; however, no development has been reported by the company since 1998 [ 201836 ]. Studies undertaken by 1996 with these compounds are disclosed in world patent WO-09606082.</Summary><CompaniesSecondary><Company>Pfizer Pharmaceuticals Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Allergy</Indication><Indication>Cardiovascular disease</Indication><Indication>Common cold</Indication><Indication>Inflammatory disease</Indication><Indication>Pain</Indication></IndicationsSecondary><ActionsSecondary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Vasoconstrictor</Action></ActionsSecondary><AddedDate>1996-03-19T00:00:00Z</AddedDate></Drug><Drug id="54087" name="Rhinox" lastModificationDate="2017-03-07T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>SinoFresh Healthcare Inc</CompanyOriginator><Technologies><Technology>Nasal formulation local</Technology><Technology>Nasal systemic formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>SinoFresh Healthcare was investigating Rhinox, an intranasal spray formulation of cethylpyridinium chloride, an ammonium salt antiseptic, for the potential treatment of sinusitis, methicillin-resistant Staphylococcus aureus (MRSA) infection and the common &lt;b&gt;cold&lt;/b&gt;. In September 2005, SinoFresh concluded its first pre-IND meeting with the FDA. At that time, phase III trials for sinusitis were expected by October 2006 [ 624484 ]. In 2002, SinoFresh Nasal Spray, an OTC version of Rhinox, was launched in the US </Summary><CompaniesSecondary><Company>SinoFresh Healthcare Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Common cold</Indication><Indication>MRSA infection</Indication><Indication>Sinusitis</Indication></IndicationsSecondary><ActionsSecondary><Action>Antibacterial</Action><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2005-09-22T00:00:00Z</AddedDate></Drug><Drug id="69798" name="hydrocodone polistirex + chlorpheniramine polistirex (extended-release capsule, cough/upper respiratory symptoms), Covidien" lastModificationDate="2018-01-18T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Covidien plc</CompanyOriginator><CompaniesPrimary><Company>Hi-Tech Pharmacal Co Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cough</Indication><Indication>Respiratory disorder</Indication></IndicationsPrimary><ActionsPrimary><Action>Histamine receptor antagonist</Action><Action>Opioid receptor agonist</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary> developed and launched TussiCaps, an extended-release capsule formulation, using an ion-exchange polymer matrix, of the narcotic antitussive hydrocodone polistirex and the antihistamine chlorpheniramine polistirex, for the treatment of allergy- or &lt;b&gt;cold&lt;/b&gt;-associated cough and upper respiratory symptoms [ 1163319 ], [ 1163293 ]. In September 2008, TussiCaps was launched in the US [ 1163319 ]. In August 2011, Hi-Tech Pharmacal had acquired marketing rights [ 1217619 ].</Summary><CompaniesSecondary><Company>Covidien plc</Company></CompaniesSecondary><ActionsSecondary><Action>Antitussive</Action></ActionsSecondary><AddedDate>2011-01-25T00:00:00Z</AddedDate></Drug><Drug id="15593" name="eculizumab" lastModificationDate="2019-07-02T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Alexion Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Alexion Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Brain hemorrhage</Indication><Indication>Hemolytic uremic syndrome</Indication><Indication>Kidney transplant rejection</Indication><Indication>Kidney transplantation</Indication><Indication>Liver transplantation</Indication><Indication>Myasthenia gravis</Indication><Indication>Neuromyelitis optica</Indication><Indication>Paroxysmal nocturnal hemoglobinuria</Indication><Indication>Thrombotic microangiopathy</Indication></IndicationsPrimary><ActionsPrimary><Action>Complement C5 factor inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><Summary>obtained and analyzed [ 1523716 ]; however, no further development has been reported. Eculizumab was previously being developed for Guillain Barre syndrome and &lt;b&gt;cold&lt;/b&gt; agglutinin disease. In August 2015, a phase II study was initiated in patients with Guillain Barre syndrome [ 1677639 ]. In February 2011, a phase II study in patients with &lt;b&gt;cold&lt;/b&gt; agglutinin disease began [ 1310753 ]; however, no further development has since been reported.</Summary><IndicationsSecondary><Indication>Antiphospholipid syndrome</Indication><Indication>Cold agglutinin disease</Indication><Indication>Dermatomyositis</Indication><Indication>Dry age related macular degeneration</Indication><Indication>Glomerulonephritis</Indication><Indication>Guillain Barre syndrome</Indication><Indication>Nephritis</Indication><Indication>Neuropathy</Indication><Indication>Pemphigus</Indication><Indication>Psoriasis</Indication><Indication>Rheumatoid arthritis</Indication><Indication>Systemic lupus erythematosus</Indication></IndicationsSecondary><ActionsSecondary><Action>Immunomodulator</Action></ActionsSecondary><AddedDate>1997-07-29T00:00:00Z</AddedDate></Drug><Drug id="92584" name="CL-AT-313" lastModificationDate="2019-06-11T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Charleston Laboratories Inc</CompanyOriginator><CompaniesPrimary><Company>Charleston Laboratories Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Allergy</Indication><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Liquid formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Charleston Laboratories is investigating CL-AT-313, a liquid formulation of a combination of hydrocodone bitartrate and undisclosed therapeutics, for the potential treatment of cough and other upper respiratory allergies. In September 2014, the drug was listed as being in preclinical development [ 1592012 ], [ 1592322 ]. In November 2018, this was still the case [ 2160738 ].</Summary><ActionsSecondary><Action>Antitussive</Action></ActionsSecondary><AddedDate>2014-09-10T00:00:00Z</AddedDate></Drug><Drug id="84858" name="UI04LDP180CT" lastModificationDate="2014-12-22T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Korea United Pharm Inc</CompanyOriginator><ActionsPrimary><Action>Opioid receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. Korea United Pharm was investigating UI04LDP180CT, a non-opioid antitussive agent, for the potential treatment of cough. In April 2013, a formulation study was underway [ 1411536 ].</Summary><CompaniesSecondary><Company>Korea United Pharm Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cough</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action></ActionsSecondary><AddedDate>2013-05-10T00:00:00Z</AddedDate></Drug><Drug id="75326" name="GSK-2339345" lastModificationDate="2016-12-26T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>GlaxoSmithKline plc</CompanyOriginator><ActionsPrimary><Action>Voltage gated sodium channel inhibitor</Action></ActionsPrimary><Technologies><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>GlaxoSmithKline was developing GSK-2339345, a voltage-gated sodium channel inhibitor, for the potential inhaled treatment of cough [ 1252308 ], [ 1421169 ]. In November 2013, a phase II trial was initiated [ 1452835 ]. However, in March 2015, the drug was no longer listed on the company's development pipeline [ 1643398 ].</Summary><CompaniesSecondary><Company>GlaxoSmithKline plc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cough</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action></ActionsSecondary><AddedDate>2012-01-05T00:00:00Z</AddedDate></Drug><Drug id="30072" name="lesogaberan" lastModificationDate="2018-05-23T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>AstraZeneca plc</CompanyOriginator><CompaniesPrimary><Company>University of Manchester</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cough</Indication></IndicationsPrimary><ActionsPrimary><Action>GABA B receptor agonist</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>The University of Manchester , as part of the Medical Research Council / AstraZeneca compound collaboration, is developing lesogaberan (AZD-3355, AZ-11941831, presumed AR-H061746), a GABA B agonist as an antitussive for the potential treatment of chronic cough [ 1350273 ]. In April 2015, a phase II trial was initiated in the UK for the treatment of patients with refractory chronic cough [ 1916176 ]; in May 2018, first clinical data were presented [ 2035123 ], [ 2036313 ]. AstraZeneca was developing</Summary><CompaniesSecondary><Company>AstraZeneca plc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Gastroesophageal reflux</Indication></IndicationsSecondary><ActionsSecondary><Action>Antitussive</Action></ActionsSecondary><AddedDate>2000-08-10T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="34" label="&lt; 100"/><FilterOption count="14" label="â¥ 100 and  250"/><FilterOption count="4" label="â¥ 250 and  500"/><FilterOption count="2" label="â¥ 500 and  1000"/><FilterOption count="10" label="â¥ 1000"/></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="100"><FilterOption id="59620" count="113" label="Unspecified drug target"/><FilterOption id="1625" count="88" label="Antitussive"/><FilterOption id="991" count="79" label="Antiviral"/><FilterOption id="2953" count="78" label="Anti-inflammatory"/><FilterOption id="1545" count="67" label="Anticancer"/><FilterOption id="2946" count="65" label="Analgesic"/><FilterOption id="397" count="61" label="Mucolytic agent"/><FilterOption id="1615" count="24" label="Neuroprotectant"/><FilterOption id="12378" count="23" label="Prophylactic vaccine"/><FilterOption id="1594" count="21" label="Antibacterial"/><FilterOption id="393" count="20" label="Immunostimulant"/><FilterOption id="1470" count="18" label="Respiratory system agent"/><FilterOption id="1626" count="14" label="Expectorant"/><FilterOption id="55685" count="13" label="Anticancer monoclonal antibody"/><FilterOption id="2657" count="13" label="Antihypertensive"/><FilterOption id="12364" count="13" label="Live attenuated viral vaccine"/><FilterOption id="1596" count="12" label="Immunomodulator"/><FilterOption id="1532" count="12" label="Viral replication inhibitor"/><FilterOption id="284" count="11" label="Nootropic agent"/><FilterOption id="5555" count="10" label="PET contrast agent"/><FilterOption id="524" count="9" label="Adjuvant"/><FilterOption id="1589" count="9" label="Apoptosis stimulator"/><FilterOption id="4155" count="9" label="Imaging agent"/><FilterOption id="5720" count="9" label="Radiodiagnostic"/><FilterOption id="62255" count="8" label="Anticancer protein kinase inhibitor"/><FilterOption id="74" count="8" label="Antioxidant agent"/><FilterOption id="7220" count="8" label="Neoplasm diagnostic agent"/><FilterOption id="7761" count="8" label="T-lymphocyte stimulator"/><FilterOption id="4780" count="7" label="Adenovirus based gene therapy"/><FilterOption id="2942" count="7" label="Anxiolytic"/><FilterOption id="646" count="7" label="Bronchodilator"/><FilterOption id="7211" count="7" label="CNS diagnostic agent"/><FilterOption id="15184" count="7" label="Systemic antipsoriatic product"/><FilterOption id="70" count="6" label="Anticonvulsant agent"/><FilterOption id="2947" count="6" label="Antiparkinsonian"/><FilterOption id="2943" count="6" label="Antipsychotic"/><FilterOption id="7294" count="6" label="Antisense oligonucleotide inhibitor"/><FilterOption id="1590" count="6" label="Apoptosis inhibitor"/><FilterOption id="1552" count="6" label="Radioimmunotherapeutic"/><FilterOption id="12379" count="6" label="Therapeutic vaccine"/><FilterOption id="388" count="6" label="Vasodilator"/><FilterOption id="2941" count="5" label="Antidepressant"/><FilterOption id="1593" count="5" label="Antimicrobial"/><FilterOption id="2659" count="5" label="Cardioprotectant"/><FilterOption id="7210" count="5" label="Cardiovascular diagnostic agent"/><FilterOption id="767" count="5" label="Cell cycle inhibitor"/><FilterOption id="7212" count="5" label="Endocrine diagnostic agent"/><FilterOption id="399" count="5" label="Hypoglycemic agent"/><FilterOption id="12370" count="5" label="Recombinant viral vector vaccine"/><FilterOption id="15180" count="5" label="Topical antipruritic product"/><FilterOption id="2660" count="5" label="Vasoprotectant"/><FilterOption id="2970" count="4" label="Anti-emetic"/><FilterOption id="55684" count="4" label="Anticancer antibody"/><FilterOption id="965" count="4" label="Cardiovascular agent"/><FilterOption id="7213" count="4" label="Gastrointestinal diagnostic agent"/><FilterOption id="783" count="4" label="HSV replication inhibitor"/><FilterOption id="396" count="4" label="Immunosuppressant"/><FilterOption id="285" count="4" label="Norepinephrine uptake inhibitor"/><FilterOption id="12372" count="4" label="Protein subunit vaccine"/><FilterOption id="7293" count="4" label="Synergist"/><FilterOption id="1720" count="4" label="Virus uptake inhibitor"/><FilterOption id="173472" count="3" label="Dendritic cell stimulator"/><FilterOption id="664" count="3" label="Fibrosuppressant"/><FilterOption id="250" count="3" label="Mast cell degranulation inhibitor"/><FilterOption id="2576" count="3" label="Microtubule stabilizer"/><FilterOption id="5557" count="3" label="Muscle relaxant"/><FilterOption id="1408" count="3" label="Muscle system agent"/><FilterOption id="4405" count="3" label="Radioimmunodiagnostic"/><FilterOption id="1610" count="3" label="Surfactant"/><FilterOption id="15181" count="3" label="Systemic antipruritic product"/><FilterOption id="15189" count="3" label="Topical dermatological antiviral product"/><FilterOption id="3" count="2" label="5-HT uptake inhibitor"/><FilterOption id="61" count="2" label="Angiogenesis inhibitor"/><FilterOption id="50" count="2" label="Anticancer alkylating agent"/><FilterOption id="1840" count="2" label="Appetite suppressant"/><FilterOption id="803" count="2" label="DNA modulator"/><FilterOption id="1748" count="2" label="Fungicide"/><FilterOption id="12366" count="2" label="Inactivated bacterial vaccine"/><FilterOption id="7751" count="2" label="Macrophage stimulator"/><FilterOption id="173474" count="2" label="Microbiome modulator"/><FilterOption id="4158" count="2" label="MRI imaging agent"/><FilterOption id="1606" count="2" label="Mucosal protective"/><FilterOption id="173716" count="2" label="Natural killer T-lymphocyte stimulator"/><FilterOption id="799" count="2" label="Photosensitizer"/><FilterOption id="312" count="2" label="Platelet aggregation inhibitor"/><FilterOption id="959" count="2" label="Protectant"/><FilterOption id="415" count="2" label="Radical donator"/><FilterOption id="1617" count="2" label="Radiopharmaceutical"/><FilterOption id="5721" count="2" label="Radiotherapeutic"/><FilterOption id="26035" count="2" label="siRNA agent"/><FilterOption id="712" count="2" label="Smooth muscle relaxant"/><FilterOption id="12371" count="2" label="Subunit vaccine"/><FilterOption id="12380" count="2" label="Unspecified vaccine"/><FilterOption id="7292" count="2" label="Vulnerary agent"/><FilterOption id="4781" count="1" label="Adeno-associated virus based gene therapy"/><FilterOption id="902" count="1" label="Adrenergic modulator"/><FilterOption id="62" count="1" label="Angiogenesis stimulator"/><FilterOption id="2667" count="1" label="Antiarteriosclerotic"/><FilterOption id="1569" count="1" label="Anticancer antimetabolite"/><FilterOption id="1586" count="1" label="Anticancer chemosensitizer"/></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="19"><FilterOption id="4" count="126" label="Drug - Development/Commercialization License"/><FilterOption id="13" count="73" label="Drug - Funding"/><FilterOption id="3" count="53" label="Drug - Early Research/Development"/><FilterOption id="5" count="51" label="Drug - Commercialization License"/><FilterOption id="6" count="46" label="Drug - Manufacturing/Supply"/><FilterOption id="7" count="44" label="Drug - Development Services"/><FilterOption id="11" count="29" label="Patent - Exclusive Rights"/><FilterOption id="10" count="28" label="Technology - Other Proprietary"/><FilterOption id="14" count="25" label="Drug - Asset Divestment"/><FilterOption id="2" count="23" label="Drug - Screening/Evaluation"/><FilterOption id="8" count="14" label="Technology - Delivery/Formulation"/><FilterOption id="12" count="11" label="Patent - Non-Exclusive Rights"/><FilterOption id="15" count="7" label="Drug - CRADA"/><FilterOption id="20" count="6" label="Company - M&amp;A (in whole or part)"/><FilterOption id="19" count="2" label="Company - Joint Venture"/><FilterOption id="16" count="2" label="Technology - Asset Divestment"/><FilterOption id="1" count="1" label="Drug - Discovery/Design"/><FilterOption id="21" count="1" label="Patent - Litigation Settlement"/><FilterOption id="9" count="1" label="Technology - Target Validation"/></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="20" label="&lt; 100"/><FilterOption count="10" label="â¥ 100 and  250"/><FilterOption count="3" label="â¥ 250 and  500"/><FilterOption count="6" label="â¥ 500 and  1000"/><FilterOption count="11" label="â¥ 1000"/></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="208" label="= 0"/><FilterOption count="100" label="&gt; 1 and â¤ 1"/><FilterOption count="43" label="&gt; 2 and â¤ 2"/><FilterOption count="28" label="&gt; 3 and â¤ 3"/><FilterOption count="20" label="&gt; 4 and â¤ 4"/><FilterOption count="14" label="&gt; 5 and â¤ 5"/><FilterOption count="36" label="&gt; 6 and â¤ 10"/><FilterOption count="12" label="&gt; 11"/></Filter><Filter label="Technologies" name="technologies" total="100"><FilterOption id="762" count="304" label="Small molecule therapeutic"/><FilterOption id="761" count="140" label="Biological therapeutic"/><FilterOption id="585" count="119" label="Oral formulation"/><FilterOption id="648" count="59" label="Intravenous formulation"/><FilterOption id="175" count="41" label="Drug combination"/><FilterOption id="595" count="40" label="Tablet formulation"/><FilterOption id="616" count="35" label="Inhalant formulation"/><FilterOption id="766" count="35" label="Parenteral formulation unspecified"/><FilterOption id="80" count="31" label="Peptide"/><FilterOption id="586" count="28" label="Capsule formulation"/><FilterOption id="740" count="26" label="Infusion"/><FilterOption id="85" count="25" label="Protein recombinant"/><FilterOption id="746" count="23" label="Solution"/><FilterOption id="647" count="23" label="Subcutaneous formulation"/><FilterOption id="611" count="21" label="Dermatological formulation"/><FilterOption id="573" count="19" label="Immunoglobulin-G"/><FilterOption id="660" count="19" label="Oral sustained release formulation"/><FilterOption id="724" count="19" label="Radiolabeling"/><FilterOption id="1647" count="18" label="Natural product"/><FilterOption id="731" count="17" label="Imaging"/><FilterOption id="603" count="17" label="Systemic formulation unspecified"/><FilterOption id="62" count="15" label="Virus recombinant"/><FilterOption id="617" count="14" label="Aerosol formulation inhalant"/><FilterOption id="169" count="12" label="Monoclonal antibody humanized"/><FilterOption id="593" count="12" label="Oral liquid formulation"/><FilterOption id="589" count="12" label="Sustained release formulation"/><FilterOption id="1263" count="11" label="Immuno-oncology"/><FilterOption id="605" count="11" label="Nasal systemic formulation"/><FilterOption id="612" count="10" label="Emulsion dermatological"/><FilterOption id="898" count="10" label="Formulation powder"/><FilterOption id="751" count="9" label="Film coating"/><FilterOption id="651" count="9" label="Intramuscular formulation"/><FilterOption id="168" count="9" label="Monoclonal antibody human"/><FilterOption id="159" count="9" label="Oligosaccharide"/><FilterOption id="619" count="8" label="Nasal formulation local"/><FilterOption id="618" count="8" label="Powder formulation inhalant"/><FilterOption id="1652" count="8" label="Prodrug"/><FilterOption id="558" count="8" label="Transdermal formulation"/><FilterOption id="103" count="7" label="Oligonucleotide"/><FilterOption id="750" count="6" label="Freeze drying"/><FilterOption id="596" count="6" label="Injectable formulation"/><FilterOption id="569" count="6" label="Oligonucleotide antisense"/><FilterOption id="620" count="6" label="Ophthalmic formulation"/><FilterOption id="594" count="6" label="Oral suspension formulation"/><FilterOption id="66" count="5" label="Antibiotic"/><FilterOption id="347" count="5" label="Intratumoral formulation"/><FilterOption id="894" count="5" label="Liquid formulation"/><FilterOption id="348" count="5" label="PEGylated formulation"/><FilterOption id="84" count="5" label="Protein fusion"/><FilterOption id="630" count="5" label="Stereochemistry"/><FilterOption id="805" count="4" label="Daily dosing"/><FilterOption id="775" count="4" label="Dermatological gel formulation"/><FilterOption id="142" count="4" label="Liposome formulation"/><FilterOption id="51" count="4" label="Monoclonal antibody"/><FilterOption id="1667" count="4" label="Nanoparticle formulation dermatological"/><FilterOption id="1" count="3" label="Antibody"/><FilterOption id="680" count="3" label="Buccal formulation systemic"/><FilterOption id="641" count="3" label="Controlled release formulation"/><FilterOption id="112" count="3" label="DNA technology"/><FilterOption id="74" count="3" label="Glycoprotein"/><FilterOption id="743" count="3" label="Granule"/><FilterOption id="764" count="3" label="Local formulation unspecified"/><FilterOption id="1668" count="3" label="Nanoparticle formulation"/><FilterOption id="599" count="3" label="Nanoparticle formulation injectable"/><FilterOption id="777" count="3" label="Nasal formulation"/><FilterOption id="659" count="3" label="Ophthalmic liquid formulation"/><FilterOption id="600" count="3" label="Patch formulation"/><FilterOption id="901" count="3" label="Recombinant enzyme"/><FilterOption id="90" count="3" label="Steroid"/><FilterOption id="180" count="2" label="Antibody fragment"/><FilterOption id="67" count="2" label="Antigen"/><FilterOption id="962" count="2" label="Biosimilar product"/><FilterOption id="723" count="2" label="Drug coating"/><FilterOption id="590" count="2" label="Enteric coated formulation"/><FilterOption id="897" count="2" label="Formulation aerosol"/><FilterOption id="896" count="2" label="Formulation solid oral"/><FilterOption id="851" count="2" label="Intradermal formulation"/><FilterOption id="654" count="2" label="Intrathecal formulation"/><FilterOption id="753" count="2" label="Microparticle formulation"/><FilterOption id="171" count="2" label="Monoclonal antibody conjugated"/><FilterOption id="170" count="2" label="Multivalent monoclonal antibody"/><FilterOption id="701" count="2" label="Nucleoside synthesis"/><FilterOption id="559" count="2" label="Oral controlled release formulation"/><FilterOption id="776" count="2" label="Oral gel formulation"/><FilterOption id="661" count="2" label="Oral quick release formulation"/><FilterOption id="902" count="2" label="Orally disintegrating tablet"/><FilterOption id="667" count="2" label="Peptidomimetic"/><FilterOption id="207" count="2" label="Protein conjugated"/><FilterOption id="745" count="2" label="Suspension"/><FilterOption id="606" count="2" label="Transmucosal formulation"/><FilterOption id="601" count="1" label="Absorption enhancer transdermal"/><FilterOption id="615" count="1" label="Aerosol formulation dermatological"/><FilterOption id="1164" count="1" label="Antibody drug conjugate"/><FilterOption id="582" count="1" label="Antibody polyclonal"/><FilterOption id="56" count="1" label="Bacteria recombinant"/><FilterOption id="609" count="1" label="Buccal formulation local"/><FilterOption id="127" count="1" label="Cell culture"/><FilterOption id="165" count="1" label="Cell delivery system"/><FilterOption id="570" count="1" label="Cell therapy"/><FilterOption id="1247" count="1" label="Chimeric antigen receptor T cell therapy"/></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="100"><FilterOption count="72" label="1996-02-16"/><FilterOption count="5" label="2014-04-09"/><FilterOption count="3" label="2009-10-19"/><FilterOption count="3" label="2011-09-14"/><FilterOption count="3" label="2012-12-28"/><FilterOption count="2" label="2004-12-21"/><FilterOption count="2" label="2010-04-16"/><FilterOption count="2" label="2010-08-09"/><FilterOption count="2" label="2010-09-07"/><FilterOption count="2" label="2010-09-20"/><FilterOption count="2" label="2011-07-22"/><FilterOption count="2" label="2011-08-23"/><FilterOption count="2" label="2012-10-15"/><FilterOption count="2" label="2012-10-26"/><FilterOption count="2" label="2013-03-04"/><FilterOption count="2" label="2013-04-16"/><FilterOption count="2" label="2013-06-04"/><FilterOption count="2" label="2014-05-26"/><FilterOption count="2" label="2014-07-03"/><FilterOption count="2" label="2014-07-07"/><FilterOption count="2" label="2015-05-13"/><FilterOption count="2" label="2017-02-18"/><FilterOption count="2" label="2017-07-08"/><FilterOption count="2" label="2018-05-11"/><FilterOption count="2" label="2019-05-22"/><FilterOption count="1" label="1996-03-08"/><FilterOption count="1" label="1996-03-19"/><FilterOption count="1" label="1996-03-28"/><FilterOption count="1" label="1996-04-17"/><FilterOption count="1" label="1996-06-06"/><FilterOption count="1" label="1996-07-26"/><FilterOption count="1" label="1996-08-06"/><FilterOption count="1" label="1996-08-15"/><FilterOption count="1" label="1996-08-19"/><FilterOption count="1" label="1996-08-27"/><FilterOption count="1" label="1996-09-13"/><FilterOption count="1" label="1996-09-16"/><FilterOption count="1" label="1996-10-14"/><FilterOption count="1" label="1996-10-16"/><FilterOption count="1" label="1996-11-18"/><FilterOption count="1" label="1996-11-27"/><FilterOption count="1" label="1996-12-02"/><FilterOption count="1" label="1996-12-12"/><FilterOption count="1" label="1996-12-13"/><FilterOption count="1" label="1996-12-23"/><FilterOption count="1" label="1997-01-08"/><FilterOption count="1" label="1997-02-12"/><FilterOption count="1" label="1997-04-15"/><FilterOption count="1" label="1997-07-02"/><FilterOption count="1" label="1997-07-16"/><FilterOption count="1" label="1997-07-17"/><FilterOption count="1" label="1997-07-18"/><FilterOption count="1" label="1997-07-29"/><FilterOption count="1" label="1997-10-02"/><FilterOption count="1" label="1997-10-13"/><FilterOption count="1" label="1997-11-13"/><FilterOption count="1" label="1997-12-05"/><FilterOption count="1" label="1997-12-17"/><FilterOption count="1" label="1998-01-29"/><FilterOption count="1" label="1998-03-02"/><FilterOption count="1" label="1998-04-02"/><FilterOption count="1" label="1998-04-22"/><FilterOption count="1" label="1998-07-07"/><FilterOption count="1" label="1998-09-09"/><FilterOption count="1" label="1998-09-30"/><FilterOption count="1" label="1998-10-21"/><FilterOption count="1" label="1999-01-11"/><FilterOption count="1" label="1999-02-23"/><FilterOption count="1" label="1999-06-11"/><FilterOption count="1" label="1999-07-01"/><FilterOption count="1" label="1999-07-08"/><FilterOption count="1" label="1999-07-12"/><FilterOption count="1" label="1999-08-19"/><FilterOption count="1" label="1999-09-10"/><FilterOption count="1" label="1999-09-15"/><FilterOption count="1" label="1999-10-04"/><FilterOption count="1" label="1999-12-24"/><FilterOption count="1" label="2000-01-25"/><FilterOption count="1" label="2000-03-01"/><FilterOption count="1" label="2000-04-06"/><FilterOption count="1" label="2000-05-05"/><FilterOption count="1" label="2000-05-24"/><FilterOption count="1" label="2000-06-15"/><FilterOption count="1" label="2000-06-16"/><FilterOption count="1" label="2000-06-20"/><FilterOption count="1" label="2000-06-23"/><FilterOption count="1" label="2000-08-10"/><FilterOption count="1" label="2000-09-18"/><FilterOption count="1" label="2001-03-08"/><FilterOption count="1" label="2001-05-11"/><FilterOption count="1" label="2001-07-12"/><FilterOption count="1" label="2001-07-20"/><FilterOption count="1" label="2001-10-02"/><FilterOption count="1" label="2001-11-26"/><FilterOption count="1" label="2002-01-10"/><FilterOption count="1" label="2002-03-01"/><FilterOption count="1" label="2002-03-04"/><FilterOption count="1" label="2002-04-08"/><FilterOption count="1" label="2002-04-16"/><FilterOption count="1" label="2002-05-30"/></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="2"><FilterOption count="401" label="No"/><FilterOption count="60" label="Yes"/></Filter><Filter label="Secondary Companies" name="companiesSecondary" total="100"><FilterOption id="28355" count="14" label="GlaxoSmithKline plc"/><FilterOption id="18767" count="10" label="Pfizer Inc"/><FilterOption id="18077" count="8" label="Merck &amp; Co Inc"/><FilterOption id="15262" count="8" label="Vernalis plc"/><FilterOption id="19711" count="7" label="Schering-Plough Corp"/><FilterOption id="19962" count="7" label="SmithKline Beecham plc"/><FilterOption id="14109" count="6" label="Amgen Inc"/><FilterOption id="13601" count="5" label="Abbott Laboratories"/><FilterOption id="14190" count="5" label="AstraZeneca plc"/><FilterOption id="17924" count="5" label="Genaera Corp"/><FilterOption id="23137" count="5" label="Novartis AG"/><FilterOption id="15334" count="4" label="Cell Genesys Inc"/><FilterOption id="19453" count="4" label="Genentech Inc"/><FilterOption id="17332" count="4" label="Johnson &amp; Johnson"/><FilterOption id="29264" count="4" label="Lipocine Inc"/><FilterOption id="21210" count="4" label="Medimmune Vaccines Inc"/><FilterOption id="20983" count="4" label="Mitsubishi Pharma Corp"/><FilterOption id="26488" count="3" label="Agouron Pharmaceuticals Inc"/><FilterOption id="14042" count="3" label="Allergan Inc"/><FilterOption id="14455" count="3" label="Bayer AG"/><FilterOption id="14881" count="3" label="Boehringer Ingelheim International GmbH"/><FilterOption id="24236" count="3" label="Cambridge Antibody Technology Group plc"/><FilterOption id="1043326" count="3" label="Chiesi USA Inc"/><FilterOption id="15518" count="3" label="Cold Spring Harbor Laboratory"/><FilterOption id="17810" count="3" label="Eli Lilly &amp; Co"/><FilterOption id="16453" count="3" label="Glaxo Group Ltd"/><FilterOption id="20586" count="3" label="Hebrew University of Jerusalem"/><FilterOption id="17269" count="3" label="Ionis Pharmaceuticals Inc"/><FilterOption id="17327" count="3" label="Japan Tobacco Inc"/><FilterOption id="16074" count="3" label="Laboratorios Dr Esteve SA"/><FilterOption id="20518" count="3" label="National Institutes of Health"/><FilterOption id="25584" count="3" label="Pfizer Vaccines"/><FilterOption id="26494" count="3" label="Sanofi-Synthelabo"/><FilterOption id="1034793" count="3" label="Tris Pharma Inc"/><FilterOption id="23780" count="2" label="Actelion Ltd"/><FilterOption id="17995" count="2" label="Adams Respiratory Therapeutics Inc"/><FilterOption id="18226" count="2" label="Agennix USA Inc"/><FilterOption id="29779" count="2" label="Ahn-Gook Pharmaceuticals Co Ltd"/><FilterOption id="1009448" count="2" label="Allon Therapeutics Inc"/><FilterOption id="14289" count="2" label="Aradigm Corp"/><FilterOption id="1013295" count="2" label="Astellas Pharma Inc"/><FilterOption id="23133" count="2" label="Aviragen Therapeutics Inc"/><FilterOption id="14729" count="2" label="Biogen Inc (FL)"/><FilterOption id="1005244" count="2" label="Biogen Inc"/><FilterOption id="15065" count="2" label="Bristol-Myers Squibb Co"/><FilterOption id="21955" count="2" label="Calydon Inc"/><FilterOption id="1011870" count="2" label="Chelsea Therapeutics Inc"/><FilterOption id="1067963" count="2" label="Conrig Pharma ApS"/><FilterOption id="18607" count="2" label="Correvio Pharma Corp"/><FilterOption id="15337" count="2" label="CTI BioPharma Corp"/><FilterOption id="15652" count="2" label="Dekk-Tec Inc"/><FilterOption id="22692" count="2" label="Eli Lilly Japan KK"/><FilterOption id="26192" count="2" label="Endo Health Solutions Inc"/><FilterOption id="27183" count="2" label="EpiCept Corp"/><FilterOption id="1063153" count="2" label="Exodos Life Science Partners"/><FilterOption id="25202" count="2" label="GPC Biotech AG"/><FilterOption id="16611" count="2" label="Hanmi Pharmaceutical Co Ltd"/><FilterOption id="17085" count="2" label="IDEC Pharmaceuticals Corp"/><FilterOption id="24182" count="2" label="Idun Pharmaceuticals Inc"/><FilterOption id="1006925" count="2" label="Jiangsu Hengrui Medicine Co Ltd"/><FilterOption id="20596" count="2" label="Johns Hopkins University"/><FilterOption id="29481" count="2" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"/><FilterOption id="1041409" count="2" label="MabVax Therapeutics Inc"/><FilterOption id="23065" count="2" label="Maxim Pharmaceuticals Inc"/><FilterOption id="18954" count="2" label="Meda AB"/><FilterOption id="18008" count="2" label="MedImmune LLC"/><FilterOption id="22122" count="2" label="Memorial Sloan-Kettering Cancer Center"/><FilterOption id="19862" count="2" label="Merck Serono SA"/><FilterOption id="1041266" count="2" label="Microgen State Scientific Industrial Company"/><FilterOption id="18229" count="2" label="Mitsubishi-Tokyo Pharmaceuticals Inc"/><FilterOption id="19446" count="2" label="Roche Holding AG"/><FilterOption id="27801" count="2" label="Sakai Chemical Industry Co Ltd"/><FilterOption id="19046" count="2" label="Shire ViroPharma, Inc"/><FilterOption id="14333" count="2" label="TOLMAR Therapeutics Inc"/><FilterOption id="1087839" count="2" label="True North Therapeutics"/><FilterOption id="20623" count="2" label="University of Michigan"/><FilterOption id="29124" count="2" label="Welfide Corp"/><FilterOption id="20967" count="2" label="Yamanouchi Pharmaceutical Co Ltd"/><FilterOption id="20978" count="2" label="Yissum Research Development Co"/><FilterOption id="20999" count="2" label="Zambon Co SpA"/><FilterOption id="1009856" count="2" label="ZIOPHARM Oncology Inc"/><FilterOption id="28429" count="1" label="Academia Sinica"/><FilterOption id="15515" count="1" label="Acea Pharmaceuticals Inc"/><FilterOption id="24347" count="1" label="Acorda Therapeutics Inc"/><FilterOption id="22342" count="1" label="Aderis Pharmaceuticals Inc"/><FilterOption id="1012444" count="1" label="Adimmune Corp"/><FilterOption id="1051282" count="1" label="Afferent Pharmaceuticals"/><FilterOption id="22211" count="1" label="Affymax Inc"/><FilterOption id="1014305" count="1" label="airPharma"/><FilterOption id="24993" count="1" label="ALG Co"/><FilterOption id="1015867" count="1" label="ALIGN Pharmaceuticals LLC"/><FilterOption id="1088700" count="1" label="Allergan plc"/><FilterOption id="30843" count="1" label="ALS Therapy Development Institute"/><FilterOption id="13726" count="1" label="AMAG Pharmaceuticals Inc"/><FilterOption id="21737" count="1" label="Amgen Research (Munich) GmbH"/><FilterOption id="1019156" count="1" label="Amistad Pharma SAS"/><FilterOption id="27120" count="1" label="ANI Pharmaceuticals Inc"/><FilterOption id="1032852" count="1" label="APT Pharmaceuticals Inc"/><FilterOption id="1059246" count="1" label="Ario Pharma Ltd"/><FilterOption id="20972" count="1" label="Astellas Pharma Europe Ltd"/></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="100"><FilterOption id="82" count="37" label="Cough"/><FilterOption id="88" count="19" label="Cystic fibrosis"/><FilterOption id="517" count="17" label="Common cold"/><FilterOption id="651" count="16" label="Cancer"/><FilterOption id="1295" count="16" label="Neuropathic pain"/><FilterOption id="191" count="14" label="Influenza virus infection"/><FilterOption id="20" count="14" label="Pain"/><FilterOption id="1185" count="11" label="Chronic obstructive pulmonary disease"/><FilterOption id="31" count="10" label="Asthma"/><FilterOption id="49" count="9" label="Breast tumor"/><FilterOption id="157" count="9" label="Herpes simplex virus infection"/><FilterOption id="1262" count="8" label="Non-small-cell lung cancer"/><FilterOption id="14" count="7" label="Alzheimers disease"/><FilterOption id="725" count="7" label="Solid tumor"/><FilterOption id="623" count="5" label="Head and neck tumor"/><FilterOption id="205" count="5" label="Melanoma"/><FilterOption id="319" count="5" label="Non-Hodgkin lymphoma"/><FilterOption id="249" count="5" label="Pancreas tumor"/><FilterOption id="276" count="5" label="Prostate tumor"/><FilterOption id="711" count="5" label="Respiratory disease"/><FilterOption id="3713" count="4" label="Advanced solid tumor"/><FilterOption id="12" count="4" label="Allergy"/><FilterOption id="2432" count="4" label="Bronchiectasis"/><FilterOption id="1488" count="4" label="Chronic bronchitis"/><FilterOption id="1745" count="4" label="Follicle center lymphoma"/><FilterOption id="1108" count="4" label="Glioma"/><FilterOption id="188" count="4" label="Inflammatory disease"/><FilterOption id="2989" count="4" label="Kidney transplant rejection"/><FilterOption id="3665" count="4" label="Metastatic non small cell lung cancer"/><FilterOption id="255" count="4" label="Parkinsons disease"/><FilterOption id="279" count="4" label="Pruritus"/><FilterOption id="281" count="4" label="Psoriasis"/><FilterOption id="291" count="4" label="Rheumatoid arthritis"/><FilterOption id="3257" count="4" label="Stage IV melanoma"/><FilterOption id="1728" count="3" label="Acute lymphoblastic leukemia"/><FilterOption id="1731" count="3" label="Acute myelogenous leukemia"/><FilterOption id="3002" count="3" label="Adult onset Stills disease"/><FilterOption id="36" count="3" label="Autoimmune disease"/><FilterOption id="316" count="3" label="B-cell lymphoma"/><FilterOption id="50" count="3" label="Bronchitis"/><FilterOption id="1734" count="3" label="Chronic lymphocytic leukemia"/><FilterOption id="2644" count="3" label="Cold agglutinin disease"/><FilterOption id="989" count="3" label="Colorectal tumor"/><FilterOption id="3601" count="3" label="Cryopyrin associated periodic syndrome"/><FilterOption id="101" count="3" label="Diabetic neuropathy"/><FilterOption id="1749" count="3" label="Diffuse large B-cell lymphoma"/><FilterOption id="3602" count="3" label="Familial cold autoinflammatory syndrome"/><FilterOption id="134" count="3" label="Glaucoma"/><FilterOption id="2454" count="3" label="Glioblastoma"/><FilterOption id="1767" count="3" label="Hepatocellular carcinoma"/><FilterOption id="161" count="3" label="Hodgkins disease"/><FilterOption id="164" count="3" label="HSV-1 infection"/><FilterOption id="3771" count="3" label="Idiopathic pulmonary fibrosis"/><FilterOption id="3003" count="3" label="Juvenile rheumatoid arthritis"/><FilterOption id="3657" count="3" label="Metastatic breast cancer"/><FilterOption id="3222" count="3" label="Muckle Wells syndrome"/><FilterOption id="280" count="3" label="Pseudomonas aeruginosa infection"/><FilterOption id="3510" count="3" label="Pulmonary artery hypertension"/><FilterOption id="299" count="3" label="Schizophrenia"/><FilterOption id="3040" count="2" label="Acne vulgaris"/><FilterOption id="1487" count="2" label="Acute bronchitis"/><FilterOption id="2438" count="2" label="Allergic conjunctivitis"/><FilterOption id="1645" count="2" label="Arterial occlusive disease"/><FilterOption id="2643" count="2" label="Autoimmune hemolytic anemia"/><FilterOption id="1484" count="2" label="Bacterial respiratory tract infection"/><FilterOption id="2380" count="2" label="Bladder cancer"/><FilterOption id="1754" count="2" label="Cutaneous T-cell lymphoma"/><FilterOption id="3923" count="2" label="Diabetic peripheral neuropathy"/><FilterOption id="113" count="2" label="Endometriosis"/><FilterOption id="186" count="2" label="Erectile dysfunction"/><FilterOption id="3244" count="2" label="Familial mediterranean fever"/><FilterOption id="2527" count="2" label="Fibromyalgia"/><FilterOption id="2425" count="2" label="Frontotemporal dementia"/><FilterOption id="3865" count="2" label="Genital herpes"/><FilterOption id="136" count="2" label="Gout"/><FilterOption id="141" count="2" label="Guillain Barre syndrome"/><FilterOption id="153" count="2" label="Hepatitis C virus infection"/><FilterOption id="4682" count="2" label="Histiocytosis"/><FilterOption id="158" count="2" label="HIV infection"/><FilterOption id="159" count="2" label="HIV-1 infection"/><FilterOption id="746" count="2" label="Infectious disease"/><FilterOption id="2512" count="2" label="Interstitial cystitis"/><FilterOption id="3676" count="2" label="Ischemic stroke"/><FilterOption id="201" count="2" label="Liver disease"/><FilterOption id="2988" count="2" label="Liver transplant rejection"/><FilterOption id="2983" count="2" label="Liver transplantation"/><FilterOption id="3437" count="2" label="Lower back pain"/><FilterOption id="755" count="2" label="Lung tumor"/><FilterOption id="203" count="2" label="Lymphoma"/><FilterOption id="1744" count="2" label="Mantle cell lymphoma"/><FilterOption id="3235" count="2" label="Merkel cell carcinoma"/><FilterOption id="3669" count="2" label="Metastatic pancreas cancer"/><FilterOption id="3122" count="2" label="Mild cognitive impairment"/><FilterOption id="212" count="2" label="Motor neurone disease"/><FilterOption id="758" count="2" label="Multidrug resistant infection"/><FilterOption id="213" count="2" label="Multiple sclerosis"/><FilterOption id="240" count="2" label="Ocular hypertension"/><FilterOption id="245" count="2" label="Osteoarthritis"/><FilterOption id="1297" count="2" label="Paroxysmal nocturnal hemoglobinuria"/><FilterOption id="3239" count="2" label="Portal hypertension"/></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="100"><FilterOption id="82" count="40" label="Cough"/><FilterOption id="651" count="36" label="Cancer"/><FilterOption id="20" count="32" label="Pain"/><FilterOption id="31" count="27" label="Asthma"/><FilterOption id="517" count="18" label="Common cold"/><FilterOption id="88" count="17" label="Cystic fibrosis"/><FilterOption id="1185" count="16" label="Chronic obstructive pulmonary disease"/><FilterOption id="292" count="13" label="Rhinovirus infection"/><FilterOption id="1295" count="12" label="Neuropathic pain"/><FilterOption id="57" count="11" label="Cardiovascular disease"/><FilterOption id="188" count="9" label="Inflammatory disease"/><FilterOption id="191" count="9" label="Influenza virus infection"/><FilterOption id="711" count="9" label="Respiratory disease"/><FilterOption id="14" count="8" label="Alzheimers disease"/><FilterOption id="158" count="8" label="HIV infection"/><FilterOption id="281" count="8" label="Psoriasis"/><FilterOption id="291" count="8" label="Rheumatoid arthritis"/><FilterOption id="49" count="7" label="Breast tumor"/><FilterOption id="157" count="7" label="Herpes simplex virus infection"/><FilterOption id="205" count="7" label="Melanoma"/><FilterOption id="213" count="7" label="Multiple sclerosis"/><FilterOption id="233" count="7" label="Neurodegenerative disease"/><FilterOption id="799" count="7" label="Ovary tumor"/><FilterOption id="989" count="6" label="Colorectal tumor"/><FilterOption id="212" count="6" label="Motor neurone disease"/><FilterOption id="837" count="6" label="Non-insulin dependent diabetes"/><FilterOption id="245" count="6" label="Osteoarthritis"/><FilterOption id="264" count="6" label="Picornavirus infection"/><FilterOption id="25" count="5" label="Anxiety disorder"/><FilterOption id="55" count="5" label="Cardiac failure"/><FilterOption id="1488" count="5" label="Chronic bronchitis"/><FilterOption id="84" count="5" label="Crohns disease"/><FilterOption id="153" count="5" label="Hepatitis C virus infection"/><FilterOption id="178" count="5" label="Hypertension"/><FilterOption id="189" count="5" label="Inflammatory bowel disease"/><FilterOption id="65" count="5" label="Stroke"/><FilterOption id="1107" count="4" label="Allergic rhinitis"/><FilterOption id="40" count="4" label="Bacterial infection"/><FilterOption id="50" count="4" label="Bronchitis"/><FilterOption id="353" count="4" label="Cognitive disorder"/><FilterOption id="93" count="4" label="Depression"/><FilterOption id="119" count="4" label="Epilepsy"/><FilterOption id="152" count="4" label="Hepatitis B virus infection"/><FilterOption id="170" count="4" label="Huntingtons chorea"/><FilterOption id="283" count="4" label="Lung disease"/><FilterOption id="755" count="4" label="Lung tumor"/><FilterOption id="3657" count="4" label="Metastatic breast cancer"/><FilterOption id="1828" count="4" label="Multiple myeloma"/><FilterOption id="255" count="4" label="Parkinsons disease"/><FilterOption id="276" count="4" label="Prostate tumor"/><FilterOption id="279" count="4" label="Pruritus"/><FilterOption id="478" count="4" label="Raynauds disease"/><FilterOption id="299" count="4" label="Schizophrenia"/><FilterOption id="52" count="4" label="Skin burns"/><FilterOption id="515" count="4" label="Transplant rejection"/><FilterOption id="23" count="3" label="Angina"/><FilterOption id="36" count="3" label="Autoimmune disease"/><FilterOption id="1734" count="3" label="Chronic lymphocytic leukemia"/><FilterOption id="430" count="3" label="Coxsackie virus infection"/><FilterOption id="89" count="3" label="Cytomegalovirus infection"/><FilterOption id="97" count="3" label="Diabetes mellitus"/><FilterOption id="1749" count="3" label="Diffuse large B-cell lymphoma"/><FilterOption id="110" count="3" label="Emesis"/><FilterOption id="1276" count="3" label="Female sexual dysfunction"/><FilterOption id="2527" count="3" label="Fibromyalgia"/><FilterOption id="3246" count="3" label="Hormone refractory prostate cancer"/><FilterOption id="185" count="3" label="Immune disorder"/><FilterOption id="4250" count="3" label="Metastatic renal cell carcinoma"/><FilterOption id="210" count="3" label="Migraine"/><FilterOption id="1272" count="3" label="Myelodysplastic syndrome"/><FilterOption id="2376" count="3" label="Overactive bladder"/><FilterOption id="249" count="3" label="Pancreas tumor"/><FilterOption id="3300" count="3" label="Postherpetic neuralgia"/><FilterOption id="1766" count="3" label="Renal cell carcinoma"/><FilterOption id="1005" count="3" label="Unidentified indication"/><FilterOption id="187" count="3" label="Urinary incontinence"/><FilterOption id="344" count="3" label="Viral infection"/><FilterOption id="3713" count="2" label="Advanced solid tumor"/><FilterOption id="11" count="2" label="Alcoholism"/><FilterOption id="12" count="2" label="Allergy"/><FilterOption id="17" count="2" label="Anemia"/><FilterOption id="1006" count="2" label="Aplastic anemia"/><FilterOption id="2977" count="2" label="Aseptic meningitis"/><FilterOption id="33" count="2" label="Atherosclerosis"/><FilterOption id="1102" count="2" label="Atopic dermatitis"/><FilterOption id="1484" count="2" label="Bacterial respiratory tract infection"/><FilterOption id="768" count="2" label="Behcets disease"/><FilterOption id="834" count="2" label="Brain injury"/><FilterOption id="425" count="2" label="Cachexia"/><FilterOption id="62" count="2" label="Cerebral infarction"/><FilterOption id="64" count="2" label="Cerebrovascular disease"/><FilterOption id="80" count="2" label="Coronary artery disease"/><FilterOption id="1782" count="2" label="Coronavirus infection"/><FilterOption id="90" count="2" label="Dementia"/><FilterOption id="94" count="2" label="Dermatitis"/><FilterOption id="2475" count="2" label="Dermatomyositis"/><FilterOption id="101" count="2" label="Diabetic neuropathy"/><FilterOption id="2020" count="2" label="Duchenne dystrophy"/><FilterOption id="118" count="2" label="Enterovirus infection"/><FilterOption id="121" count="2" label="Factor VIII deficiency"/></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="14"><FilterOption id="1" count="80" label="Orphan Drug"/><FilterOption id="2" count="37" label="Fast Track"/><FilterOption id="3" count="16" label="Breakthrough Therapy"/><FilterOption id="11" count="12" label="Priority Review"/><FilterOption id="9" count="10" label="Paediatric Investigation Plan"/><FilterOption id="10" count="4" label="PRIME"/><FilterOption id="5" count="3" label="Accelerated Approval"/><FilterOption id="13" count="3" label="Rare Pediatric Disease"/><FilterOption id="16" count="2" label="Promising Innovative Medicine"/><FilterOption id="4" count="1" label="Advanced Therapy Medicinal Product"/><FilterOption id="6" count="1" label="Animal Rule"/><FilterOption id="12" count="1" label="Qualified Infectious Disease Product"/><FilterOption id="14" count="1" label="Sakigake"/><FilterOption id="19" count="1" label="Special Review Project"/></Filter><Filter label="Primary Actions" name="actionsPrimary" total="100"><FilterOption id="138" count="9" label="DNA polymerase inhibitor"/><FilterOption id="199" count="8" label="Histamine H1 receptor antagonist"/><FilterOption id="293" count="7" label="Opioid receptor mu agonist"/><FilterOption id="4865" count="7" label="P2X3 purinoceptor antagonist"/><FilterOption id="15422" count="7" label="TRP cation channel M8 inhibitor"/><FilterOption id="266" count="6" label="NK1 receptor antagonist"/><FilterOption id="281" count="5" label="NMDA receptor antagonist"/><FilterOption id="287" count="5" label="Opioid receptor agonist"/><FilterOption id="6938" count="5" label="Vanilloid VR1 antagonist"/><FilterOption id="154" count="4" label="Elastase inhibitor"/><FilterOption id="7682" count="4" label="Protein tyrosine phosphatase-1B inhibitor"/><FilterOption id="40695" count="4" label="TRP cation channel A1 inhibitor"/><FilterOption id="40" count="3" label="Beta 2 adrenoceptor agonist"/><FilterOption id="2664" count="3" label="Heparin agonist"/><FilterOption id="198" count="3" label="Histamine receptor antagonist"/><FilterOption id="498" count="3" label="Sodium channel inhibitor"/><FilterOption id="6" count="2" label="5-HT 1a receptor agonist"/><FilterOption id="3859" count="2" label="AKT protein kinase inhibitor"/><FilterOption id="29" count="2" label="Alpha adrenoceptor agonist"/><FilterOption id="16715" count="2" label="Amiloride sensitive sodium channel inhibitor"/><FilterOption id="621" count="2" label="Amyloid protein deposition inhibitor"/><FilterOption id="5083" count="2" label="B-lymphocyte antigen CD20 modulator"/><FilterOption id="91" count="2" label="Bradykinin receptor antagonist"/><FilterOption id="2590" count="2" label="Calcium channel inhibitor N-type"/><FilterOption id="2603" count="2" label="Caspase inhibitor"/><FilterOption id="1104" count="2" label="Chloride channel modulator"/><FilterOption id="15172" count="2" label="Complement C1s subcomponent inhibitor"/><FilterOption id="151630" count="2" label="CRISPR associated endonuclease Cas9 modulator"/><FilterOption id="21480" count="2" label="CSF2 gene stimulator"/><FilterOption id="5482" count="2" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="44162" count="2" label="Deoxyribonuclease I stimulator"/><FilterOption id="1303" count="2" label="Deoxyribonuclease modulator"/><FilterOption id="562" count="2" label="Deoxyribonuclease stimulator"/><FilterOption id="135" count="2" label="DHFR inhibitor"/><FilterOption id="665" count="2" label="Folate receptor antagonist"/><FilterOption id="7583" count="2" label="Glycogen synthase kinase-3 inhibitor"/><FilterOption id="200" count="2" label="Histamine H2 receptor agonist"/><FilterOption id="1584" count="2" label="IL-12 receptor antagonist"/><FilterOption id="9748" count="2" label="IL-23 antagonist"/><FilterOption id="483" count="2" label="Interferon alpha ligand"/><FilterOption id="12479" count="2" label="Interleukin-1 beta ligand inhibitor"/><FilterOption id="10295" count="2" label="LDL receptor related protein-1 modulator"/><FilterOption id="255" count="2" label="MAO B inhibitor"/><FilterOption id="2653" count="2" label="Nuclear factor kappa B inhibitor"/><FilterOption id="288" count="2" label="Opioid receptor antagonist"/><FilterOption id="291" count="2" label="Opioid receptor kappa agonist"/><FilterOption id="1115" count="2" label="Opioid receptor modulator"/><FilterOption id="294" count="2" label="Opioid receptor mu antagonist"/><FilterOption id="2634" count="2" label="ORL1 receptor agonist"/><FilterOption id="6687" count="2" label="PARP stimulator"/><FilterOption id="321" count="2" label="PGE1 agonist"/><FilterOption id="434" count="2" label="PGF2 alpha agonist"/><FilterOption id="1575" count="2" label="Phosphoinositide 3-kinase inhibitor"/><FilterOption id="753" count="2" label="Retinoic acid receptor agonist"/><FilterOption id="89933" count="2" label="Stimulator of interferon genes protein stimulator"/><FilterOption id="2426" count="2" label="Tau deposition inhibitor"/><FilterOption id="15068" count="2" label="Thioredoxin modulator"/><FilterOption id="7827" count="2" label="TLR-9 agonist"/><FilterOption id="1807" count="2" label="Viral protease modulator"/><FilterOption id="9274" count="1" label="2,5-Oligoadenylate synthetase stimulator"/><FilterOption id="585" count="1" label="5-HT 2a receptor antagonist"/><FilterOption id="1" count="1" label="5-HT receptor agonist"/><FilterOption id="247" count="1" label="5-Lipoxygenase inhibitor"/><FilterOption id="6284" count="1" label="Actin antagonist"/><FilterOption id="6282" count="1" label="Actin modulator"/><FilterOption id="26642" count="1" label="Activity-dependent neuroprotector modulator"/><FilterOption id="5136" count="1" label="ADP ribosyl cyclase-1 inhibitor"/><FilterOption id="28" count="1" label="Adrenergic receptor agonist"/><FilterOption id="18934" count="1" label="Agouti related protein inhibitor"/><FilterOption id="815" count="1" label="Albumin modulator"/><FilterOption id="6927" count="1" label="Alpha 2C adrenoceptor antagonist"/><FilterOption id="53" count="1" label="AMPA receptor antagonist"/><FilterOption id="1173" count="1" label="Angiotensin II AT-2 receptor antagonist"/><FilterOption id="12791" count="1" label="Anthrax protective antigen inhibitor"/><FilterOption id="6979" count="1" label="Apolipoprotein C3 antagonist"/><FilterOption id="21361" count="1" label="Aquaporin 4 inhibitor"/><FilterOption id="529" count="1" label="ATPase inhibitor"/><FilterOption id="4418" count="1" label="Aurora protein kinase 1 inhibitor"/><FilterOption id="4420" count="1" label="Aurora protein kinase 2 inhibitor"/><FilterOption id="5080" count="1" label="B-lymphocyte antigen CD19 modulator"/><FilterOption id="5085" count="1" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="5091" count="1" label="B-lymphocyte cell adhesion molecule inhibitor"/><FilterOption id="37" count="1" label="Beta adrenoceptor agonist"/><FilterOption id="7343" count="1" label="Beta amyloid antagonist"/><FilterOption id="2420" count="1" label="Beta amyloid modulator"/><FilterOption id="86" count="1" label="Beta lactamase inhibitor"/><FilterOption id="7573" count="1" label="Beta secretase modulator"/><FilterOption id="15707" count="1" label="Beta-catenin modulator"/><FilterOption id="789" count="1" label="Bradykinin B2 receptor antagonist"/><FilterOption id="50877" count="1" label="CACNA2D1 calcium channel subunit stimulator"/><FilterOption id="93" count="1" label="Calcium channel inhibitor"/><FilterOption id="2589" count="1" label="Calcium channel inhibitor T-type"/><FilterOption id="1098" count="1" label="Calcium channel modulator"/><FilterOption id="9420" count="1" label="Calcium channel modulator T-type"/><FilterOption id="14194" count="1" label="cAMP responsive element binding protein modulator"/><FilterOption id="2577" count="1" label="Cannabinoid CB1 receptor modulator"/><FilterOption id="2578" count="1" label="Cannabinoid CB2 receptor modulator"/><FilterOption id="1551" count="1" label="Cannabinoid receptor antagonist"/><FilterOption id="1901" count="1" label="Cathepsin K inhibitor"/><FilterOption id="5049" count="1" label="CD11a agonist"/></Filter><Filter label="Primary Companies" name="companiesPrimary" total="100"><FilterOption id="23137" count="9" label="Novartis AG"/><FilterOption id="28355" count="6" label="GlaxoSmithKline plc"/><FilterOption id="1088700" count="5" label="Allergan plc"/><FilterOption id="17810" count="5" label="Eli Lilly &amp; Co"/><FilterOption id="14061" count="4" label="Almirall Prodesfarma SA"/><FilterOption id="17058" count="4" label="Bausch Health Companies Inc"/><FilterOption id="14455" count="4" label="Bayer AG"/><FilterOption id="15414" count="4" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="19453" count="4" label="Genentech Inc"/><FilterOption id="18077" count="4" label="Merck &amp; Co Inc"/><FilterOption id="1014809" count="4" label="NanoViricides Inc"/><FilterOption id="1019381" count="4" label="NovaBiotics Ltd"/><FilterOption id="18767" count="4" label="Pfizer Inc"/><FilterOption id="24154" count="4" label="Recordati SpA"/><FilterOption id="19446" count="4" label="Roche Holding AG"/><FilterOption id="1034793" count="4" label="Tris Pharma Inc"/><FilterOption id="1039298" count="3" label="Beijing CoSci Med-Tech Co Ltd"/><FilterOption id="1093682" count="3" label="DepYmed Inc"/><FilterOption id="1033225" count="3" label="Hawthorn Pharmaceuticals Inc"/><FilterOption id="1045514" count="3" label="Mundipharma International Corp Ltd"/><FilterOption id="1034163" count="3" label="Nexgen Pharma Inc"/><FilterOption id="1071782" count="3" label="Oneday - Biotech &amp; Pharma Ltd"/><FilterOption id="1009681" count="3" label="Parion Sciences Inc"/><FilterOption id="1111132" count="3" label="Spriaso LLC"/><FilterOption id="1072507" count="2" label="AbbVie Inc"/><FilterOption id="29779" count="2" label="Ahn-Gook Pharmaceuticals Co Ltd"/><FilterOption id="1043999" count="2" label="AlgiPharma AS"/><FilterOption id="1055752" count="2" label="Alitair Pharmaceuticals Inc"/><FilterOption id="1018183" count="2" label="AngioChem Inc"/><FilterOption id="17793" count="2" label="Avanir Pharmaceuticals Inc"/><FilterOption id="1108165" count="2" label="Aytu BioScience Inc"/><FilterOption id="1005244" count="2" label="Biogen Inc"/><FilterOption id="1143045" count="2" label="Bioverativ Inc"/><FilterOption id="21794" count="2" label="CASI Pharmaceuticals Inc"/><FilterOption id="1058127" count="2" label="Cold Genesys Inc"/><FilterOption id="15518" count="2" label="Cold Spring Harbor Laboratory"/><FilterOption id="15587" count="2" label="Daewoong Pharmaceutical Co Ltd"/><FilterOption id="1017506" count="2" label="Daiichi Sankyo Co Ltd"/><FilterOption id="26028" count="2" label="Dompe Group"/><FilterOption id="29708" count="2" label="Ferring Pharmaceuticals SA"/><FilterOption id="16587" count="2" label="Grunenthal GmbH"/><FilterOption id="17204" count="2" label="Immunomedics Inc"/><FilterOption id="26997" count="2" label="Janssen Biotech Inc"/><FilterOption id="1090652" count="2" label="JHL Biotech Inc"/><FilterOption id="21932" count="2" label="Lupin Ltd"/><FilterOption id="26786" count="2" label="MegaPharm Ltd"/><FilterOption id="20983" count="2" label="Mitsubishi Pharma Corp"/><FilterOption id="1035060" count="2" label="Mitsubishi Tanabe Pharma Corp"/><FilterOption id="21388" count="2" label="Neopharm Ltd"/><FilterOption id="1084428" count="2" label="Ockham Biotech Ltd"/><FilterOption id="19214" count="2" label="Regeneron Pharmaceuticals Inc"/><FilterOption id="19670" count="2" label="Santen Pharmaceutical Co Ltd"/><FilterOption id="1150261" count="2" label="Synspira"/><FilterOption id="1022888" count="2" label="Vaxart Inc"/><FilterOption id="1112925" count="1" label="7 Hills Pharma Llc"/><FilterOption id="13601" count="1" label="Abbott Laboratories"/><FilterOption id="1093047" count="1" label="Abivax SA"/><FilterOption id="1179286" count="1" label="Acrotech Biopharma LLC"/><FilterOption id="1036096" count="1" label="Admedus Immunotherapies"/><FilterOption id="1039923" count="1" label="Aduro BioTech Inc"/><FilterOption id="1049277" count="1" label="Aeromics LLC"/><FilterOption id="14317" count="1" label="AGC Bioscience"/><FilterOption id="1104556" count="1" label="Akcea Therapeutics Inc"/><FilterOption id="28817" count="1" label="Akorn Inc"/><FilterOption id="18478" count="1" label="Alcon Inc"/><FilterOption id="13979" count="1" label="Alexion Pharmaceuticals Inc"/><FilterOption id="1153354" count="1" label="Alfasigma SpA"/><FilterOption id="1069037" count="1" label="Allergan Pharmaceuticals Ireland"/><FilterOption id="21162" count="1" label="Amarillo Biosciences Inc"/><FilterOption id="14109" count="1" label="Amgen Inc"/><FilterOption id="1079984" count="1" label="Annexon Biosciences"/><FilterOption id="1008173" count="1" label="AOP Orphan Pharmaceuticals AG"/><FilterOption id="1063900" count="1" label="Apellis Pharmaceuticals Inc"/><FilterOption id="1033114" count="1" label="Apogenix GmbH"/><FilterOption id="1143621" count="1" label="ApolloBio Corp"/><FilterOption id="24356" count="1" label="Apricus Biosciences Inc"/><FilterOption id="1059414" count="1" label="Arch Oncology"/><FilterOption id="14303" count="1" label="Asahi Kasei Pharma Corp"/><FilterOption id="1007879" count="1" label="Ascendis Pharma A/S"/><FilterOption id="1013295" count="1" label="Astellas Pharma Inc"/><FilterOption id="16890" count="1" label="Astra Hassle AB"/><FilterOption id="1127578" count="1" label="Attenua Inc"/><FilterOption id="23946" count="1" label="Aus Bio Ltd"/><FilterOption id="1018507" count="1" label="Avid Radiopharmaceuticals Inc"/><FilterOption id="1180621" count="1" label="Axalbion SA"/><FilterOption id="1052204" count="1" label="Beech Tree Labs Inc"/><FilterOption id="1063251" count="1" label="BeiGene Co Ltd"/><FilterOption id="1018445" count="1" label="Beijing Tide Pharmaceutical Co Ltd"/><FilterOption id="18500" count="1" label="BELLUS Health Inc"/><FilterOption id="1062473" count="1" label="BioAegis Therapeutics Inc"/><FilterOption id="14695" count="1" label="BioCryst Pharmaceuticals Inc"/><FilterOption id="21164" count="1" label="BioDelivery Sciences International Inc"/><FilterOption id="30212" count="1" label="BioDiem Ltd"/><FilterOption id="1011989" count="1" label="Biokine Therapeutics Ltd"/><FilterOption id="1008903" count="1" label="BioLineRx Ltd"/><FilterOption id="1047330" count="1" label="BioNTech SE"/><FilterOption id="15016" count="1" label="Biopure Corp"/><FilterOption id="14834" count="1" label="Biota Holdings Ltd"/><FilterOption id="22546" count="1" label="Boehringer Ingelheim GmbH"/><FilterOption id="14987" count="1" label="Boryung Pharm Co Ltd"/></Filter><Filter label="Highest Phase" name="phaseHighest" total="12"><FilterOption id="NDR" count="136" label="No Development Reported"/><FilterOption id="L" count="87" label="Launched"/><FilterOption id="DR" count="76" label="Discovery"/><FilterOption id="DX" count="57" label="Discontinued"/><FilterOption id="C2" count="47" label="Phase 2 Clinical"/><FilterOption id="C3" count="25" label="Phase 3 Clinical"/><FilterOption id="C1" count="16" label="Phase 1 Clinical"/><FilterOption id="PR" count="6" label="Pre-registration"/><FilterOption id="R" count="4" label="Registered"/><FilterOption id="CU" count="3" label="Clinical"/><FilterOption id="W" count="2" label="Withdrawn"/><FilterOption id="S" count="2" label="Suspended"/></Filter></Filters></drugResultsOutput>